Prof Janet Dunn

Job Title

Professor of Clinical Trials & Hd of Cancer Trials

Department

WMS - Warwick Clinical Trials Unit

Phone

75847

J.A.Dunn@warwick.ac.uk

Web Link

Professor Janet Dunn is Head of Cancer Trials at Warwick Clinical Trials Unit (CTU) at Warwick Medical School, University of Warwick. She has over 30 years clinical trials experience. She qualified with a BSc (2i) in Mathematical Sciences in 1987, an MSc in Applied Statistics in 1989 from Manchester and gained a PhD in Medicine in 2004 from Birmingham. She started as a junior statistician in 1988 at the Cancer Research UK Clinical Trials Unit, University of Birmingham, working up to Deputy Director and then Assistant Director responsible for over 25 phase III multi-centre randomised clinical trials. She was instrumental in establishing Birmingham as one of the initial 6 national accredited cancer clinical trials units. In 2003 she was awarded a USA National Cancer Institute fellowship which involved a 6 month sabbatical at Washington DC assessing smoking as a risk factor for pancreatic cancer. She is involved in National Cancer Research Institute (NCRI) breast, colorectal, pancreatic, myeloma, melanoma, and head & neck cancer trials and is currently on the NCRI breast cancer clinical studies group. In January 2006 she was appointed as Professor of Clinical Trials and head of cancer trials at Warwick CTU and was instrumental in establishing cancer trials. Warwick CTU gained full UKCRN registration in 2008 and moved into their new building in 2009 having secured money from Advantage West Midlands Science City and the Wolfson Foundation. Her research interests include the evaluation of prognostic and predictive factors in cancer clinical trials, and designing clinical trials to impact on clinical practice. The establishment of the National Cancer Research Network and the continued funding from Cancer Research UK has resulted in the completion of many successful UK academic trials which have challenged and changed clinical practice. In 2008 Professor Dunn was awarded National Institute of Health Research Senior Investigator status being one of the inaugural cohort of investigators contributing to applied patient centred research. She has been successful in attracting NIHR National Coordinating Centre for Health Technology Assessment (NCCHTA) grants totalling £6 million for cancer trials at Warwick. These achievements have resulted in Warwick CTU being one of the 15 NCRI badged CTUs demonstrating esteem for the Cancer trials carried out within Warwick CTU.

Biography

Azam, Ayesha S., Tsang, Yee?Wah, Thirlwall, Jenny, Kimani, Peter K., Sah, Shatrughan, Gopalakrishnan, Kishore, Boyd, Clinton, Loughrey, Maurice B., Kelly, Paul J., Boyle, David P., Salto?Tellez, Manuel, Clark, David, Ellis, Ian O., Ilyas, Mohammad, Rakha, Emad, Bickers, Adam, Roberts, Ian S. D., Soares, Maria F., Neil, Desley A. H., Takyi, Abi et al (Select to open full list), 2024.

All authors for Digital pathology for reporting histopathology samples, including cancer screening samples ? definitive evidence from a multisite study

Azam, Ayesha S., Tsang, Yee?Wah, Thirlwall, Jenny, Kimani, Peter K., Sah, Shatrughan, Gopalakrishnan, Kishore, Boyd, Clinton, Loughrey, Maurice B., Kelly, Paul J., Boyle, David P., Salto?Tellez, Manuel, Clark, David, Ellis, Ian O., Ilyas, Mohammad, Rakha, Emad, Bickers, Adam, Roberts, Ian S. D., Soares, Maria F., Neil, Desley A. H., Takyi, Abi, Raveendran, Sinthuri, Hero, Emily, Evans, Harriet, Osman, Rania, Fatima, Khunsha, Hughes, Rhian W., McIntosh, Stuart A., Moran, Gordon W., Ortiz?Fernandez?Sordo, Jacobo, Rajpoot, Nasir M., Storey, Ben, Ahmed, Imtiaz, Dunn, Janet A., Hiller, Louise, Snead, David R. J.

Digital pathology for reporting histopathology samples, including cancer screening samples ? definitive evidence from a multisite study. Histopathology
Bowcock, Stella, Atkin, Catherine, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Neal, Richard D., Planche, Tim, Karunanithi, Kamaraj, Jenkins, Stephen, Stern, Simon, Arnott, Sarah, Toth, Peter, Wandroo, Farooq, Dunn, Janet A., Drayson, Mark T., 2023. Presenting symptoms in newly diagnosed myeloma, relation to organ damage, and implications for symptom-directed screening : a secondary analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. Cancers, 15 (13)
'Yao, C., 'Osdoit, M., 'van der Noordaa, M., 'Shad, S., 'Wei, J., 'de Croze, D., 'Hamy, A -S., 'La?, M., 'Reyal, F., 'Sonke, G. S., 'Steenbruggen, T. G., 'van Seijen, M., 'Wesseling, J., 'Mart?n, M., 'del Monte-Mill?n, M., 'L?pez-Tarruella, S., 'Boughey, J. C., 'Goetz, M. P., 'Hoskin, T., 'Gould, R. et al (Select to open full list), 2022.

All authors for 'Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients

'Yao, C., 'Osdoit, M., 'van der Noordaa, M., 'Shad, S., 'Wei, J., 'de Croze, D., 'Hamy, A -S., 'La?, M., 'Reyal, F., 'Sonke, G. S., 'Steenbruggen, T. G., 'van Seijen, M., 'Wesseling, J., 'Mart?n, M., 'del Monte-Mill?n, M., 'L?pez-Tarruella, S., 'Boughey, J. C., 'Goetz, M. P., 'Hoskin, T., 'Gould, R., 'Valero, V., 'Edge, S. B., 'Abraham, J. E., 'Bartlett, J. M. S., 'Caldas, C., 'Dunn, Janet A., 'Earl, H. M., 'Hayward, L., 'Hiller, Louise, 'Provenzano, E., 'Sammut, S. J., 'Thomas, J. S., 'Cameron, D., 'Graham, A., 'Hall, P., 'Mackintosh, L., 'Fan, F., 'Godwin, A. K., 'Schwensen, K., 'Sharma, P., 'DeMichele, A. M., 'Cole, K., 'Pusztai, L., 'Kim, M., 'van?t Veer, L. J., 'Esserman, L. J., 'Symmans, W. F.

'Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients. Lancet Oncology, 23 (1), pp. 149-160
'Rischin, D., 'Mehanna, H., 'Young, R. J., 'Bressel, M., 'Dunn, Janet A., 'Corry, J., 'Soni, P., 'Fulton-Lieuw, T., 'Iqbal, G., 'Kenny, L., 'Porceddu, S., 'Wratten, C., 'Robinson, M., 'Solomon, B. J., 2022. 'Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. Annals of Oncology, 33 (8), pp. 804-813
Sammut, S., Crispin-Ortuzar, M., Chin, S. F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S. J., Abraham, J., Dunn, Janet A., Hiller, Louise, Thomas, J., Cameron, D. A., Bartlett, John M. S., Hayward, Larry, Pharoah, Paul D., Markowetz, Florian, Rueda, Oscar M., Earl, Helena M. et al (Select to open full list), 2022.

All authors for Multi-omic machine learning predictor of breast cancer therapy response

Sammut, S., Crispin-Ortuzar, M., Chin, S. F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S. J., Abraham, J., Dunn, Janet A., Hiller, Louise, Thomas, J., Cameron, D. A., Bartlett, John M. S., Hayward, Larry, Pharoah, Paul D., Markowetz, Florian, Rueda, Oscar M., Earl, Helena M., Caldas, Carlos

Multi-omic machine learning predictor of breast cancer therapy response. Nature, 601, pp. 623-629
Agbuduwe, Charles, Iqbal, Gulnaz, Cairns, David, Menzies, Tom, Dunn, Janet A., Gregory, Walter, Kaiser, Martin, Owen, Roger, Pawlyn, Charlotte, Child, J. Anthony, Davies, Faith, Morgan, Gareth J., Jackson, Graham H., Drayson, Mark T., Basu, Supratik, 2022. Clinical characteristics and outcomes of IgD myeloma : experience across UK national trials. Blood Advances, 6 (17), pp. 5113-5123
Goyal, Amit, Puri, Shama, Marshall, Andrea, Valassiadou, Kalliope, Hoosein, Moin M., Carmichael, Amtul R., Erdelyi, Gabriella, Sharma, Nisha, Dunn, Janet A., York, Joanne, 2021. A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients. Breast Cancer Research and Treatment, 185, pp. 433-440
Geach, R., Jones, L. I., Harding, S. A., Marshall, A. (Andrea), Taylor-Phillips, Sian, McKeown-Keegan, S., Dunn, Janet A., 2021. The potential utility of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening : a systematic review and meta-analysis. Clinical Radiology, 76 (2), pp. 154.e11-154.e22
Earl, Helena M., Hiller, Louise, Dunn, Janet A., Macpherson, Iain, Rea, Daniel, Hughes-Davies, Luke, McAdam, Karen, Hall, Peter, Mansi, Janine, Wheatley, Duncan, Abraham, Jean, Caldas, Carlos, Gasson, Sophie, O'Riordan, Liz, Wilcox, Maggie, Miles, David, Cameron , David, Wardley, Andrew, 2021. Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33 (1), pp. 15-19
Kosmin, Michael, Padhani, Anwar R., Gogbashian, Andrew, Woolf, David, Ah-See, Mei-Lin, Ostler, Peter, Sutherland, Stephanie, Miles, David, Noble, Jillian, Koh, Dow-Mu, Marshall, Andrea, Dunn, Janet A., Makris, Andreas, 2020. Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology, 297 (3), pp. 622-629
Conefrey, C., Donovan, J. L., Stein, R. C., Paramasivan, S., Marshall, Andrea, Bartlett, J., Cameron, D. A., Campbell, Amy, Dunn, Janet A., Earl, H., Hall, P., Harmer, V., Hughes-Davies, L., Macpherson, I., Makris, A., Morgan, A., Pinder, S. E., Poole, Christopher J., Rea, D., Rooshenas, L., 2020. Strategies to improve recruitment to a de-escalation trial : a mixed-methods study of the OPTIMA prelim trial in early breast cancer. Clinical Oncology
Jones, David A., Mistry, Pankaj, Dalby, Matthew, Fulton-Lieuw, Tessa, Kong, Anthony H., Dunn, Janet A., Mehanna, Hisham M., Gray, Alastair M., 2020. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer : Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. European Journal of Cancer Care, 124, pp. 178-185
Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Gasson, Sophie, Balmer, Claire E., Abraham, Jean E., Caldas, Carlos, Hall, Peter et al (Select to open full list), 2020.

All authors for Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT

Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Gasson, Sophie, Balmer, Claire E., Abraham, Jean E., Caldas, Carlos, Hall, Peter, Shinkins, Bethany, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M., Cameron, David A., Dunn, Janet A.

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 24 (40), pp. 1-190
Marshall, Andrea, Levine, Mark, Hill, Catherine, Hale, Danielle, Thirlwall, Jenny, Wilkie, Veronica, French, Karen, Kakkar, Ajay K., Lokare, Anand, Maraveyas, Anthony, Chapman, Oliver, Arif, Azra, Petrou, Stavros, Maredza, Mandy, Hobbs, FD Richard, Dunn, Janet A., Young, Annie M., 2020. Treatment of cancer-associated venous thromboembolism : 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D Trial. (SELECT-D: 12m). Journal of Thrombosis and Haemostasis, 18 (4), pp. 905-915
Fernando, Indrajit N., Bowden, Sarah J., Herring, Kathryn, Brookes, Cassandra L., Ahmed, Ikhlaaq, Marshall, Andrea, Grieve, Robert J., Churn, Mark, Spooner, David, Latief, Talaat N., Agrawal, Rajiv K., Brunt, Adrian M., Stevens, Andrea, Goodman, Andrew, Canney, Peter, Bishop, Jill, Ritchie, Diana, Dunn, Janet A., Poole, Christopher J., Rea, Daniel W., 2020. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB) : a randomised, phase III, trial. Radiotherapy and Oncology, 142, pp. 52-61
Bartlett, John M. S., Bayani, Jane, Kornaga, Elizabeth N., Danaher, Patrick, Crozier, Cheryl, Piper, Tammy, Yao, Cindy Q., Dunn, Janet A., Boutros, Paul C., Stein, Robert C., 2020. Computational approaches to support comparative analysis of multiparametric tests : modelling versus training. PLOS ONE, 15 (9)
Drayson, Mark T., Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen, Dawkins, Bryony, Meads, David, Hulme, Claire T., Whittaker, Anna C., Hawkey, Peter, Low, Eric, Dunn, Janet A., 2019. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 23 (62), pp. 1-94
Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis et al (Select to open full list), 2019.

All authors for 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis, Mahler?Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Abraham, Jean E, Caldas, Carlos, Hall, Peter S, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M, Cameron, David A, Dunn, Janet A.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet, 393 (10191), pp. 2599-2612
Zarkar, A., Marshall, Andrea, Davies, A., Ford, D., James, N. D., Dunn, Janet A., 2019. Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression after platinum based chemotherapy : results of the phase II CAB-B1 trial. International Journal of Cancer Research & Therapy, 4 (4)
Drayson, Mark T, Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen B., Dawkins, Bryony, Meads, David, Hulme, Claire T, Monahan, Irene, Karunanithi, Kamaraj, Dignum, Helen, Belsham, Edward, Neilson, Jeff, Harrison, Beth, Lokare, Anand, Campbell, Gavin et al (Select to open full list), 2019.

All authors for Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM) : a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

Drayson, Mark T, Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen B., Dawkins, Bryony, Meads, David, Hulme, Claire T, Monahan, Irene, Karunanithi, Kamaraj, Dignum, Helen, Belsham, Edward, Neilson, Jeff, Harrison, Beth, Lokare, Anand, Campbell, Gavin, Hamblin, Michael, Hawkey, Peter, Whittaker, Anna C, Low, Eric, Dunn, Janet A.

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM) : a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.. The Lancet. Oncology, 20 (12), pp. 1760-1772
Escala-Garcia, Maria, Guo, Qi, Dörk, Thilo, Canisius, Sander, Keeman, Renske, Dennis, Joe, Beesley, Jonathan, Lecarpentier, Julie, Bolla, Manjeet K., Wang, Qin, Abraham, Jean, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bernstein, Leslie et al (Select to open full list), 2019.

All authors for Genome-wide association study of germline variants and breast cancer-specific mortality

Escala-Garcia, Maria, Guo, Qi, Dörk, Thilo, Canisius, Sander, Keeman, Renske, Dennis, Joe, Beesley, Jonathan, Lecarpentier, Julie, Bolla, Manjeet K., Wang, Qin, Abraham, Jean, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bernstein, Leslie, Blomqvist, Carl, Boeckx, Bram, Bojesen, Stig E., Bonanni, Bernardo, Børresen-Dale, Anne-Lise, Brauch, Hiltrud, Brenner, Hermann, Brentnall, Adam, Brinton, Louise, Broberg, Per, Brock, Ian W., Brucker, Sara Y., Burwinkel, Barbara, Caldas, Carlos, Caldés, Trinidad, Campa, Daniele, Canzian, Federico, Carracedo, Angel, Carter, Brian D., Castelao, Jose E., Chang-Claude, Jenny, Chanock, Stephen J., Chenevix-Trench, Georgia, Cheng, Ting-Yuan David, Chin, Suet-Feung, Clarke, Christine L., Cordina-Duverger, Emilie, Couch, Fergus J., Cox, David G., Cox, Angela, Cross, Simon S., Czene, Kamila, Daly, Mary B., Devilee, Peter, Dunn, Janet A., Dunning, Alison M., Durcan, Lorraine, Dwek, Miriam, Earl, Helena M., Ekici, Arif B., Eliassen, A. Heather, Ellberg, Carolina, Engel, Christoph, Eriksson, Mikael, Evans, D. Gareth, Figueroa, Jonine, Flesch-Janys, Dieter, Flyger, Henrik, Gabrielson, Marike, Gago-Dominguez, Manuela, Galle, Eva, Gapstur, Susan M., García-Closas, Montserrat, García-Sáenz, José A., Gaudet, Mia M., George, Angela, Georgoulias, Vassilios, Giles, Graham G., Glendon, Gord, Goldgar, David E., González-Neira, Anna, Alnæs, Grethe I. Grenaker, Grip, Mervi, Guénel, Pascal, Haeberle, Lothar, Hahnen, Eric, Haiman, Christopher A., Håkansson, Niclas, Hall, Per, Hamann, Ute, Hankinson, Susan, Harkness, Elaine F., Harrington, Patricia A., Hart, Steven N., Hartikainen, Jaana M., Hein, Alexander, Hillemanns, Peter, Hiller, Louise, Holleczek, Bernd, Hollestelle, Antoinette, Hooning, Maartje J., Hoover, Robert N., Hopper, John L., Howell, Anthony, Huang, Guanmengqian, Humphreys, Keith, Hunter, David J., Janni, Wolfgang, John, Esther M., Jones, Michael E., Jukkola-Vuorinen, Arja, Jung, Audrey, Kaaks, Rudolf, Kabisch, Maria, Kaczmarek, Katarzyna, Kerin, Michael J., Khan, Sofia, Khusnutdinova, Elza, Kiiski, Johanna I., Kitahara, Cari M., Knight, Julia A., Ko, Yon-Dschun, Koppert, Linetta B., Kosma, Veli-Matti, Kraft, Peter, Kristensen, Vessela N., Krüger, Ute, Kühl, Tabea, Lambrechts, Diether, Le Marchand, Loic, Lee, Eunjung, Lejbkowicz, Flavio, Li, Lian, Lindblom, Annika, Lindström, Sara, Linet, Martha, Lissowska, Jolanta, Lo, Wing-Yee, Loibl, Sibylle, Lubinski, Jan, Lux, Michael P., MacInnis, Robert J., Maierthaler, Melanie, Maishman, Tom, Makalic, Enes, Mannermaa, Arto, Manoochehri, Mehdi, Manoukian, Siranoush, Margolin, Sara, Martinez, Maria Elena, Mavroudis, Dimitrios, McLean, Catriona, Meindl, Alfons, Middha, Pooja, Miller, Nicola, Milne, Roger L., Moreno, Fernando, Mulligan, Anna Marie, Mulot, Claire, Nassir, Rami, Neuhausen, Susan L., Newman, William T., Nielsen, Sune F., Nordestgaard, Børge G., Norman, Aaron, Olsson, Håkan, Orr, Nick, Pankratz, V. Shane, Park-Simon, Tjoung-Won, Perez, Jose I. A., Pérez-Barrios, Clara, Peterlongo, Paolo, Petridis, Christos, Pinchev, Mila, Prajzendanc, Karoliona, Prentice, Ross, Presneau, Nadege, Prokofieva, Darya, Pylkäs, Katri, Rack, Brigitte, Radice, Paolo, Ramachandran, Dhanya, Rennert, Gadi, Rennert, Hedy S., Rhenius, Valerie, Romero, Atocha, Roylance, Rebecca, Saloustros, Emmanouil, Sawyer, Elinor J., Schmidt, Daniel F., Schmutzler, Rita K., Schneeweiss, Andreas, Schoemaker, Minouk J., Schumacher, Fredrick, Schwentner, Lukas, Scott, Rodney J., Scott, Christopher, Seynaeve, Caroline, Shah, Mitul, Simard, Jacques, Smeets, Ann, Sohn, Christof, Southey, Melissa C., Swerdlow, Anthony J., Talhouk, Aline, Tamimi, Rulla M., Tapper, William J., Teixeira, Manuel R., Tengström, Maria, Terry, Mary Beth, Thöne, Kathrin, Tollenaar, Rob A. E. M., Tomlinson, Ian, Torres, Diana, Truong, Thérèse, Turman, Constance, Turnbull, Clare, Ulmer, Hans-Ulrich, Untch, Michael, Vachon, Celine, van Asperen, Christi J., van den Ouweland, Ans M. W., van Veen, Elke M., Wendt, Camilla, Whittemore, Alice S., Willett, Walter, Winqvist, Robert, Wolk, Alicja, Yang, Xiaohong R., Zhang, Yan, Easton, Douglas F., Fasching, Peter A., Nevanlinna, Heli, Eccles, Diana M., Pharoah, Paul D. P., Schmidt, Marjanka K.

Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 120 (6), pp. 647-657
Dunn, Janet A., Jefferson, Kieran, MacDonald, Donald, Iqbal, Gulnaz, Bland, Rosemary, 2019. Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanism. The Journal of Steroid Biochemistry and Molecular Biology, 188, pp. 134-140
Jones, Lyn I., Geach, Rebecca, Harding, Sam A., Foy, Christopher, Taylor, Victoria, Marshall, Andrea, Taylor-Phillips, Sian, Dunn, Janet A., 2019. Can mammogram readers swiftly and effectively learn to interpret first post-contrast acquisition subtracted (FAST) MRI, a type of abbreviated breast MRI? : a single centre data-interpretation study. The British Journal of Radiology, 92
Heaney, Jennifer L. J.,, Campbell, John P., Iqbal, Gulnaz, Cairns, David, Richter, Alex, Child, J. Anthony, Gregory, Walter, Jackson, Graham, Kaiser, Martin, Owen, Roger, Davies, Faith, Morgan, Gareth, Dunn, Janet A., Drayson, Mark T., 2018. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia, 32, pp. 1727-1738
Abdelrahim, Ameera, Balmer, Claire E., Jones, June, Mehanna, Hisham M., Dunn, Janet A., 2018. Considerations for a head and neck smoking cessation support programme ; a qualitative study of the challenges in quitting smoking after treatment for head and neck cancer. European Journal of Oncology Nursing, 35, pp. 54-61
Heaney, Jennifer L. J., Campbell, John P., Iqbal, Gulnaz, Cairns, David, Richter, Alex, Child, J. Anthony, Gregory, Walter, Jackson, Graham, Kaiser, Martin, Owen, Roger, Davies, Faith, Morgan, Gareth, Dunn, Janet A., Drayson, Mark T., 2018. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia, 32 (8), pp. 1727-1738
Lin, Daniel J., McConkey, Christopher C., Nankivell, Paul, Dunn, Janet A., Mehanna, Hisham, 2018. The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer : an analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England. Oral Oncology, 85, pp. 40-43
Corrie, Pippa G., Marshall, A. (Andrea)?, Nathan, P D., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C. G., Marples, M., Danson, S. J., Marshall, E., Houston, S. J., Board, R E., Waterston, A. M., Nobes, J. P., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A. et al (Select to open full list), 2018.

All authors for Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial

Corrie, Pippa G., Marshall, A. (Andrea)?, Nathan, P D., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C. G., Marples, M., Danson, S. J., Marshall, E., Houston, S. J., Board, R E., Waterston, A. M., Nobes, J. P., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A., Westwell, S., Casasola, R., Chao, D., Maraveyas, A., Patel, P. M., Ottensmeier, C. H., Farrugia, D., Humphreys, A., Eccles, B., Young, G., Barker, E. O., Harman, C., Weiss, M., Myers, K. A., Chhabra, A., Rodwell, S. H., Dunn, Janet A., Middleton, M. R.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial. Annals of Oncology, 29 (8), pp. 1843-1852
Lipplaa, Astrid, Fernandes, Ricardo, Marshall, Andrea, Lorigan, Paul, Dunn, Janet A., Myers, Kevin A, Barker, Emily, Newton-Bishop, Julia, Middleton, Mark R., Corrie, Pippa G., 2018. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. British Journal of Cancer, 119, pp. 793-800
Lee, R. J., Gremel, G., Marshall, A. (Andrea)?, Myers, K. A., Fisher, N., Dunn, Janet A., Dhomen, N., Corrie, P. G., Middleton, M. R., Lorigan, P., Marais, R., 2018. Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. Annals of Oncology, 29 (2), pp. 490-496
Fackrell, D., Marshall, A. (Andrea)?, Mistry, Pankaj, Dunn, Janet A., De Santis, Maria, Ford, D., Zarkar, A., 2018. Radical treatment of muscle-invasive bladder cancer-are options equal?. Journal of Radiation Oncology, 7 (2), pp. 181-186
Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M., 2018. Adjuvant trastuzumab duration trials in HER2 positive breast cancer : what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer, 18
Taylor-Phillips, Sian, Jenkinson, David J., Stinton, Chris, Wallis, Matthew G., Dunn, Janet A., Clarke, Aileen, 2018. Double reading in breast cancer screening : cohort evaluation in the CO-OPS trial. Radiology, 287 (3), pp. 749-757
Young, Annie M., Marshall, Andrea, Thirlwall, Jenny, Chapman, Oliver, Lokare, Anand, Hill, Catherine, Hale, Danielle, Dunn, Janet A., Lyman, Gary H., Hutchinson, Charles, MacCallum, Peter, Kakkar, Ajay, Hobbs, F. D. Richard, Petrou, Stavros, Dale, Jeremy, Poole, Christopher J., Maraveyas, Anthony, Levine, Mark, 2018. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in cancer patients with venous thromboembolism : results of a randomized trial (SELECT-D). Journal of Clinical Oncology, 36 (20), pp. 2017-2023
Fenlon, D., Morgan, A., Khambaita, P., Mistry, Pankaj, Dunn, Janet A., Ah-See, M. L., Pennery, E., Hunter, M. S., 2017. Management of hot flushes in UK breast cancer patients : clinician and patient perspectives. Journal of Psychosomatic Obstetrics & Gynecology, 38 (4), pp. 276-283
Mistry, Pankaj, Dunn, Janet A., Marshall, A. (Andrea), 2017. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. BMC Medical Research Methodology, 17 (1)
Hall, P. S., Smith, A., Hulme, C., Vargas-Palacios, A., Makris, A., Hughes-Davies, L., Dunn, Janet A., Bartlett, J. M. S., Cameron, D. A., Marshall, A., Campbell, A., Macpherson, I. R., Dan, Rea, Francis, A., Earl, H., Morgan, A., Stein, R. C., McCabe, C., 2017. Value of information analysis of multiparameter tests for chemotherapy in early breast cancer : the OPTIMA prelim trial. Value in Health, 20 (10), pp. 1311-1318
Ford, H., Marshall, A., Blazeby, J. M., Bridgewater, J. A., Wadsley, J., Coxon, F. Y., Mansoor, W., Madhusudan, S., Falk, S., Middleton, G. W., Swinson, D., Chau, I., Thompson, J., Cunningham, D., Kareclas, P., Dunn, Janet A., 2017. Cougar-02 : a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. Journal of Clinical Oncology, 31 (15)
Earl, H. M., Hiller, Louise, Dunn, Janet A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J. E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L., 2017. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer : ARTemis Trial. Annals of Oncology, 28 (8), pp. 1817-1824
Smith, A. F., Hall, P. S., Hulme, C. T., Dunn, Janet A., McConkey, Christopher C., Rahman, J. K., McCabe, C., Mehanna, H., 2017. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. European Journal of Cancer, 85, pp. 6-14
Ali, H. R., Dariush, A., Thomas, J., Provenzano, E., Dunn, Janet A., Hiller, Louise, Vallier, A.-L., Abraham, J., Piper, T., Bartlett, J. M. S., Cameron, D. A., Hayward, L., Brenton, J. D., Pharoah, P. D. P., Irwin, M. J., Walton, N. A., Earl, H. M., Caldas, C., 2017. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer : secondary analysis of the ARTemis trial. Annals of Oncology, 28 (8), pp. 1832-1835
Mehanna, H., McConkey, Christopher C., Rahman, J., Wong, W. L., Smith, A. F., Nutting, C., Hartley, A. G. J., Hall, P., Hulme, C., Patel, D., Von Zeidler, S. V., Robinson, M., Sanghera, B., Fresco, L., Dunn, Janet A., 2017. PET-NECK : a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment, 21 (17), pp. 1-122
Thomas, Jeremy St John, Provenzano, Elena, Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Gounaris, Ioannis, Abraham, Jean, Hughes-Davies, Luke, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Caldas, Carlos, Bartlett, John M. S., Cameron, David Allan, Hayward, Richard Laurence et al (Select to open full list), 2017.

All authors for Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

Thomas, Jeremy St John, Provenzano, Elena, Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Gounaris, Ioannis, Abraham, Jean, Hughes-Davies, Luke, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Caldas, Carlos, Bartlett, John M. S., Cameron, David Allan, Hayward, Richard Laurence, Earl, Helena Margaret

Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology, 30 (8), pp. 1069-1077
Pinder, S. E., Campbell, Amy, Bartlett, J. M. S., Marshall, A. (Andrea)?, Allen, D., Falzon, M., Dunn, Janet A., Makris, A., Hughes-Davies, L., Stein, R. C., 2017. Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. British Journal of Cancer, 116, pp. 859-863
Earl, Helena M., Hiller, Louise, Howard, Helen C., Dunn, Janet A., Young, Jennie, Bowden, Sarah J., McDermaid, Michelle, Waterhouse, Anna K., Wilson, Gregory, Agrawal, Rajiv, O'Reilly, Susan, Bowman, Angela, Ritchie, Diana M., Goodman, Andrew, Hickish, Tamas, McAdam, Karen, Cameron, David, Dodwell, David, Rea, Daniel W., Caldas, Carlos et al (Select to open full list), 2017.

All authors for Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo) : final 10-year follow-up of an open-label, randomised, phase 3 trial

Earl, Helena M., Hiller, Louise, Howard, Helen C., Dunn, Janet A., Young, Jennie, Bowden, Sarah J., McDermaid, Michelle, Waterhouse, Anna K., Wilson, Gregory, Agrawal, Rajiv, O'Reilly, Susan, Bowman, Angela, Ritchie, Diana M., Goodman, Andrew, Hickish, Tamas, McAdam, Karen, Cameron, David, Dodwell, David, Rea, Daniel W., Caldas, Carlos, Provenzano, Elena, Abraham, Jean E., Canney, Peter, Crown, John P., Kennedy, M John, Coleman, Robert, Leonard, Robert C., Carmichael, James A., Wardley, Andrew M., Poole, Christopher J.

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo) : final 10-year follow-up of an open-label, randomised, phase 3 trial. The Lancet Oncology, 18 (6), pp. 755-769
Meads, David M., Marshall, A. (Andrea)?, Hulme, Claire T., Dunn, Janet A., Ford, Hugo E. R., 2016. The cost effectiveness of docetaxel and active symptom control versus active symptom control alone for refractory oesophagogastric adenocarcinoma : economic analysis of the COUGAR-02 trial. PharmacoEconomics, 34 (1), pp. 33-42
Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
Bartlett, John M. S., Bayani, Jane, Marshall, A. (Andrea)?, Dunn, Janet A., Campbell, Amy, Cunningham, Carrie, Sobol, Monika S., Hall, Peter S., Poole, Christopher J., Cameron, David A., Earl, Helena M., Rea, Daniel W., Macpherson, Iain R., Canney, Peter, Francis, Adele, McCabe, Christopher, Pinder, Sarah E., Hughes-Davies, Luke, Makris, Andreas, Stein, Robert C., 2016. Comparing breast cancer multiparameter tests in the OPTIMA Prelim Trial : no test is more equal than the others. Journal of the National Cancer Institute, 108 (9)
Young, Annie M., Phillips, Jennifer, Hancocks, N. Helen, Hill, Catherine, Joshi, Neya, Marshall, A. (Andrea)?, Grumett, Joanne, Dunn, Janet A., Lokare, A., Chapman, O., 2016. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research, 140, pp. S172-S173
Francis, Adele, Stein, Robert C., Marshall, A. (Andrea?), Rea, Daniel W., Cameron, David A., Macpherson, Iain R., Earl, Helena M., Poole, Christopher J., Hall, Peter S., Bartlett, John M. S., Rooshenas, Leila, Morgan, Adrienne, Harmer, Victoria, Donovan, Jenny, Hulme, Claire, McCabe, Christopher, Pinder, Sarah E., Hughes-Davies, Luke, Makris, Andreas, Dunn, Janet A., 2016. OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) : A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions. European Journal of Surgical Oncology (EJSO), 42 (5), pp. S9-S10
Earl, Helena M, Vallier, Anne-Laure, Dunn, Janet A., Loi, Shrushma, Ogburn, Emma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian, Abraham, Jean, Wardley, Andrew, Cameron, David A, Miles, David, Gounaris, Ioannis, Plummer, Chris, Hiller, Louise, 2016. Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 115 (12), pp. 1462-1470
Ali, H. Raza, Dariush, Aliakbar, Provenzano, Elena, Bardwell, Helen, Abraham, Jean E., Iddawela, Mahesh, Vallier, Anne-Laure, Hiller, Louise, Dunn, Janet A., Bowden, Sarah J., Hickish, Tamas, McAdam, Karen, Houston, Stephen, Irwin, Mike J., Pharoah, Paul D. P., Brenton, James D., Walton, Nicholas A., Earl, Helena M., Caldas, Carlos, 2016. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 18 (1)
Janowitz, Tobias, Thuss-Patience, Peter, Marshall, A. (Andrea)?, Kang, Jung Hun, Connell, Claire, Cook, Natalie, Dunn, Janet A., Park, Se Hoon, Ford, Hugo, 2016. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma : a meta-analysis of patient-level data. British Journal of Cancer, 114 (4), pp. 381-387
Stein, Robert C., Dunn, Janet A., Bartlett, John M. S., Campbell, Amy, Marshall, A. (Andrea)?, Hall, Peter, Rooshenas, Leila, Morgan, Adrienne, Poole, Christopher, Pinder, Sarah E., Cameron, David A., Stallard, Nigel, Donovan, Jenny L., McCabe, Christopher, Hughes-Davies, Luke, Makris, Andreas, 2016. R : OPTIMA prelim : a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment, 20 (10), pp. 1-202
Thamm, Douglas, Dorling, Leila, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancakova, A., Chen, Y., Varga, T. V., Yaghootkar, H., Luan, J., Zhao, J. H., Willems, S. M., Wessel, J., Wang, S., Maruthur, N., Michailidou, K., Pirie, A., van der Lee, S. J. et al (Select to open full list), 2016.

All authors for A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancakova, A., Chen, Y., Varga, T. V., Yaghootkar, H., Luan, J., Zhao, J. H., Willems, S. M., Wessel, J., Wang, S., Maruthur, N., Michailidou, K., Pirie, A., van der Lee, S. J., Gillson, C., Al Olama, A. A., Amouyel, P., Arriola, L., Arveiler, D., Aviles-Olmos, I., Balkau, B., Barricarte, A., Barroso, I., Garcia, S. B., Bis, J. C., Blankenberg, S., Boehnke, M., Boeing, H., Boerwinkle, E., Borecki, I. B., Bork-Jensen, J., Bowden, S., Caldas, C., Caslake, M., Cupples, L. A., Cruchaga, C., Czajkowski, J., den Hoed, M., Dunn, Janet A., Earl, H. M., Ehret, G. B., Ferrannini, E., Ferrieres, J., Foltynie, T., Ford, I., Forouhi, N. G., Gianfagna, F., Gonzalez, C., Grioni, S., Hiller, Louise, Jansson, J.-H., Jorgensen, M. E., Jukema, J. W., Kaaks, R., Kee, F., Kerrison, N. D., Key, T. J., Kontto, J., Kote-Jarai, Z., Kraja, A. T., Kuulasmaa, K., Kuusisto, J., Linneberg, A., Liu, C., Marenne, G., Mohlke, K. L., Morris, A. P., Muir, K., Muller-Nurasyid, M., Munroe, P. B., Navarro, C., Nielsen, S. F., Nilsson, P. M., Nordestgaard, B. G., Packard, C. J., Palli, D., Panico, S., Peloso, G. M., Perola, M., Peters, A., Poole, C. J., Quiros, J. R., Rolandsson, O., Sacerdote, C., Salomaa, V., Sanchez, M.-J., Sattar, N., Sharp, S. J., Sims, R., Slimani, N., Smith, J. A., Thompson, D. J., Trompet, S., Tumino, R., van der A, D. L., van der Schouw, Y. T., Virtamo, J., Walker, M., Walter, K., Abraham, J. E., Amundadottir, L. T., Aponte, J. L., Butterworth, A. S., Dupuis, J., Easton, D. F., Eeles, R. A., Erdmann, J., Franks, P. W., Frayling, T. M., Hansen, T., Howson, J. M. M., Jorgensen, T., Kooner, J., Laakso, M., Langenberg, C., McCarthy, M. I., Pankow, J. S., Pedersen, O., Riboli, E., Rotter, J. I., Saleheen, D., Samani, N. J., Schunkert, H., Vollenweider, P., ORahilly, S., Deloukas, P., Danesh, J., Goodarzi, M. O., Kathiresan, S., Meigs, J. B., Ehm, M. G., Wareham, N. J., Waterworth, D. M.

A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine, 8 (341)
Mehanna, Hisham, Wong, Wai-Lup, McConkey, Christopher C., Rahman, Joy K., Robinson, Max, Hartley, Andrew G.J., Nutting, Christopher, Powell, Ned, Al-Booz, Hoda, Robinson, Martin, Junor, Elizabeth, Rizwaah, Mohammed, von Zeidler, Sandra L. V., Wieshmann, Hulya, Hulme, Claire, Smith, Alison F., Hall, Peter, Dunn, Janet A., 2016. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal Of Medicine, 374 (15), pp. 1444-1454
Hartley, A., Fong, C., Sanghera, P., Wong, W. L., McConkey, Christopher C., Rahman, J., Nutting, C. M., Al-Booz, H., Robinson, M., Junor, E., Rizwaah, M., Dunn, Janet A., Mehanna, H., 2016. Radiation therapy variation in the Randomized Phase 3 Positron Emission Tomography Neck Study. International Journal of Radiation Oncology Biology Physics, 96 (2)
Taylor-Phillips, Sian, Wallis, Matthew G., Jenkinson, David J., Adekanmbi, Victor, Parsons, Helen, Dunn, Janet A., Stallard, Nigel, Szczepura, Ala, Gates, Simon, Kearins, Olive, Duncan, Alison, Hudson, Sue, Clarke, Aileen, 2016. Effect of using the same vs different order for second readings of screening mammograms on rates of breast cancer detection : a randomized clinical trial. JAMA: The Journal of the American Medical Association, 315 (18), pp. 1956-1965
Huish, S. A., Fletcher, S., Dunn, Janet A., Hewison, M., Bland, R., 2015. Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry. Journal of Steroid Biochemistry and Molecular Biology, 164, pp. 214-217
Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2015. A 'new normal' : exploring the disruption of a poor prognostic cancer diagnosis using interviews and participant-produced photographs. Health, 19 (5), pp. 451-472
Abraham, Jean E., Hiller, Louise, Dorling, Leila, Vallier, Anne-Laure, Dunn, Janet A., Bowden, Sarah, Ingle, Susan, Jones, Linda, Hardy, Richard, Twelves, Christopher, Poole, Christopher J., Pharoah, Paul D. P., Caldas, Carlos, Earl, Helena M., 2015. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 13 (1)
Guo, Q., Schmidt, M. K., Kraft, P., Canisius, S., Chen, C., Khan, S., Tyrer, J., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Lush, M., Kar, S., Beesley, J., Dunning, A. M., Shah, M., Czene, K., Darabi, H., Eriksson, M., Lambrechts, D. et al (Select to open full list), 2015.

All authors for Identification of Novel Genetic Markers of Breast Cancer Survival

Guo, Q., Schmidt, M. K., Kraft, P., Canisius, S., Chen, C., Khan, S., Tyrer, J., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Lush, M., Kar, S., Beesley, J., Dunning, A. M., Shah, M., Czene, K., Darabi, H., Eriksson, M., Lambrechts, D., Weltens, C., Leunen, K., Bojesen, S. E., Nordestgaard, B. G., Nielsen, S. F., Flyger, H., Chang-Claude, J., Rudolph, A., Seibold, P., Flesch-Janys, D., Blomqvist, C., Aittomaki, K., Fagerholm, R., Muranen, T. A., Couch, F. J., Olson, J. E., Vachon, C., Andrulis, I. L., Knight, J. A., Glendon, G., Mulligan, A. M., Broeks, A., Hogervorst, F. B., Haiman, C. A., Henderson, B. E., Schumacher, F., Le Marchand, L., Hopper, J. L., Tsimiklis, H., Apicella, C., Southey, M. C., Cox, A., Cross, S. S., Reed, M. W. R., Giles, G. G., Milne, R. L., McLean, C., Winqvist, R., Pylkas, K., Jukkola-Vuorinen, A., Grip, M., Hooning, M. J., Hollestelle, A., Martens, J. W. M., van den Ouweland, A. M. W., Marme, F., Schneeweiss, A., Yang, R., Burwinkel, B., Figueroa, J., Chanock, S. J., Lissowska, J., Sawyer, E. J., Tomlinson, I., Kerin, M. J., Miller, N., Brenner, H., Dieffenbach, A. K., Arndt, V., Holleczek, B., Mannermaa, A., Kataja, V., Kosma, V.-M., Hartikainen, J. M., Li, J., Brand, J. S., Humphreys, K., Devilee, P., Tollenaar, R. A. E. M., Seynaeve, C., Radice, P., Peterlongo, P., Bonanni, B., Mariani, P., Fasching, P. A., Beckmann, M. W., Hein, A., Ekici, A. B., Chenevix-Trench, G., Balleine, R., Phillips, K.-A., Benitez, J., Zamora, M. P., Arias Perez, J. I., Menendez, P., Jakubowska, A., Lubinski, J., Jaworska-Bieniek, K., Durda, K., Hamann, U., Kabisch, M., Ulmer, H. U., Rudiger, T., Margolin, S., Kristensen, V., Nord, S., Evans, D. G., Abraham, J. E., Earl, H. M., Hiller, Louise, Dunn, Janet A., Bowden, S., Berg, C., Campa, D., Diver, W. R., Gapstur, S. M., Gaudet, M. M., Hankinson, S. E., Hoover, R. N., Husing, A., Kaaks, R., Machiela, M. J., Willett, W., Barrdahl, M., Canzian, F., Chin, S.-F., Caldas, C., Hunter, D. J., Lindstrom, S., Garcia-Closas, M., Hall, P., Easton, D. F., Eccles, D. M., Rahman, N., Nevanlinna, H., Pharoah, P. D. P.

Identification of Novel Genetic Markers of Breast Cancer Survival. JNCI Journal of the National Cancer Institute, 107 (5)
Treweek, Shaun, Altman, Douglas G., Bower, Peter, Campbell, Marion, Chalmers, Iain, Cotton, Seonaidh, Craig, Peter S., Crosby, David, Davidson, Peter, Devane, Declan, Duley, Lelia, Dunn, Janet A., Elbourne, Diana, Farrell, Barbara, Gamble, Carrol, Gillies, Katie, Hood, Kerry, Lang, Trudie, Littleford, Roberta, Loudon, Kirsty et al (Select to open full list), 2015.

All authors for Making randomised trials more efficient : report of the first meeting to discuss the Trial Forge platform

Treweek, Shaun, Altman, Douglas G., Bower, Peter, Campbell, Marion, Chalmers, Iain, Cotton, Seonaidh, Craig, Peter S., Crosby, David, Davidson, Peter, Devane, Declan, Duley, Lelia, Dunn, Janet A., Elbourne, Diana, Farrell, Barbara, Gamble, Carrol, Gillies, Katie, Hood, Kerry, Lang, Trudie, Littleford, Roberta, Loudon, Kirsty, McDonald, Alison, McPherson, Gladys, Nelson, Annmarie, Norrie, John, Ramsay, Craig, Sandercock, Peter, Shanahan, Daniel R., Summerskill, William, Sydes, Matthew R., Williamson, P. R. (Paula R.), Clarke, Mike

Making randomised trials more efficient : report of the first meeting to discuss the Trial Forge platform. Trials, 16 (1), pp. 1-9
Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2015. A review of the issues and challenges involved in using participant-produced photographs in nursing research. Journal of Advanced Nursing, 71 (7), pp. 1726-1737
Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2015. A review of the issues and challenges involved in using participant-produced photographs in nursing research. Journal of Advanced Nursing, 71 (7), pp. 1726-1737
Earl, Helena M., Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Abraham, Jean, Thomas, Jeremy, Provenzano, Elena, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Bartlett, John, Caldas, Carlos, Cameron, David A et al (Select to open full list), 2015.

All authors for Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis) : an open-label, randomised, phase 3 trial

Earl, Helena M., Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Abraham, Jean, Thomas, Jeremy, Provenzano, Elena, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Bartlett, John, Caldas, Carlos, Cameron, David A, Hayward, Larry

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis) : an open-label, randomised, phase 3 trial. The Lancet Oncology, 16 (6), pp. 656-666
Bartlett, J. M. S., McConkey, Christopher C., Munro, A. F., Desmedt, C., Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, H., Poole, Christopher J., Shepherd, L. E., Cardoso, F., Jensen, M., Caldas, C., Twelves, C. J., Rea, D. W., Ejlertsen, B., Di Leo, A., Pritchard, K. I., 2015. Predicting anthracycline benefit : TOP2A and CEP17-not only but also. European Journal of Cancer Care, 33 (15), pp. 1680-1687
Ali, H. R., Glont, S.- E., Blows, F. M., Provenzano, E., Dawson, S.- J., Liu, B., Hiller, Louise, Dunn, Janet A., Poole, C. J., Bowden, S., Earl, H. M., Pharoah, P. D. P., Caldas, C., 2015. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, 26 (7)
Earl, Helena, Provenzano, Elena, Abraham, Jean, Dunn, Janet A., Vallier, Anne-Laure, Gounaris, Ioannis, Hiller, Louise, 2015. Neoadjuvant trials in early breast cancer : pathological response at surgery and correlation to longer term outcomes ? what does it all mean?. BMC Medicine, 13 (1)
Bryan, R. T., Evans, T., Dunn, Janet A., Iqbal, Gulnaz, Bathers, S., Collins, S. I., James, Nicholas D., Catto, J. W. F., Wallace, D. M. A., 2015. A comparative analysis of the influence of gender, pathway delays, and risk factor exposures on the long-term outcomes of bladder cancer. European Urology Focus, 1 (1), pp. 82-89
Pirie, Ailith, Guo, Qi, Kraft, Peter, Canisius, Sander, Eccles, Diana M, Rahman, Nazneen, Nevanlinna, Heli, Chen, Constance, Khan, Sofia, Tyrer, Jonathan, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Lush, Michael, Dunning, Alison M, Shah, Mitul, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael et al (Select to open full list), 2015.

All authors for Common germline polymorphisms associated with breast cancer-specific survival

Pirie, Ailith, Guo, Qi, Kraft, Peter, Canisius, Sander, Eccles, Diana M, Rahman, Nazneen, Nevanlinna, Heli, Chen, Constance, Khan, Sofia, Tyrer, Jonathan, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Lush, Michael, Dunning, Alison M, Shah, Mitul, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael, Lambrechts, Dieter, Weltens, Caroline, Leunen, Karin, van Ongeval, Chantal, Nordestgaard, Børge G, Nielsen, Sune F, Flyger, Henrik, Rudolph, Anja, Seibold, Petra, Flesch-Janys, Dieter, Blomqvist, Carl, Aittomäki, Kristiina, Fagerholm, Rainer, Muranen, Taru A, Olsen, Janet E, Hallberg, Emily, Vachon, Celine, Knight, Julia A, Glendon, Gord, Mulligan, Anna Marie, Broeks, Annegien, Cornelissen, Sten, Haiman, Christopher A, Henderson, Brian E, Schumacher, Frederick, Le Marchand, Loic, Hopper, John L, Tsimiklis, Helen, Apicella, Carmel, Southey, Melissa C, Cross, Simon S, Reed, Malcolm WR, Giles, Graham G, Milne, Roger L, McLean, Catriona, Winqvist, Robert, Pylkäs, Katri, Jukkola-Vuorinen, Arja, Grip, Mervi, Hooning, Maartje J, Hollestelle, Antoinette, Martens, John WM, van den Ouweland, Ans MW, Marme, Federick, Schneeweiss, Andreas, Yang, Rongxi, Burwinkel, Barbara, Figueroa, Jonine, Chanock, Stephen J, Lissowska, Jolanta, Sawyer, Elinor J, Tomlinson, Ian, Kerin, Michael J, Miller, Nicola, Brenner, Hermann, Butterbach, Katja, Holleczek, Bernd, Kataja, Vesa, Kosma, Veli-Matti, Hartikainen, Jaana M, Li, Jingmei, Brand, Judith S, Humphreys, Keith, Devilee, Peter, Tollenaar, Robert AEM, Seynaeve, Caroline, Radice, Paolo, Peterlongo, Paolo, Manoukian, Siranoush, Ficarazzi, Filomena, Beckmann, Matthias W, Hein, Alexander, Ekici, Arif B, Balleine, Rosemary, Phillips, Kelly-Anne, Benitez, Javier, Zamora, M Pilar, Perez, Jose Ignacio Arias, Menéndez, Primitiva, Jakubowska, Anna, Lubinski, Jan, Gronwald, Jacek, Durda, Katarzyna, Hamann, Ute, Kabisch, Maria, Ulmer, Hans Ulrich, Rüdiger, Thomas, Margolin, Sara, Kristensen, Vessela, Nord, Siljie, Evans, D Gareth, Abraham, Jean, Earl, Helena, Poole, Christopher J, Hiller, Louise, Dunn, Janet A., Bowden, Sarah, Yang, Rose, Campa, Daniele, Diver, W Ryan, Gapstur, Susan M, Gaudet, Mia M, Hankinson, Susan, Hoover, Robert N, Hüsing, Anika, Kaaks, Rudolf, Machiela, Mitchell J, Willett, Walter, Barrdahl, Myrto, Canzian, Federico, Chin, Suet-Feung, Caldas, Carlos, Hunter, David J, Lindstrom, Sara, Garcia-Closas, Montserrat, Couch, Fergus J, Chenevix-Trench, Georgia, Mannermaa, Arto, Andrulis, Irene L, Hall, Per, Chang-Claude, Jenny, Easton, Douglas F, Bojesen, Stig E, Cox, Angela, Fasching, Peter A, Pharoah, Paul DP, Schmidt, Marjanka K

Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 17 (1)
Nelson, Laura, McKenn, Hayley D., Marshall, A. (Andrea)?, Mulrane, Laoighse, Starczynski, Jane, Storr, Sarah J., Lanigan, Fiona, Byrne, Christopher, Arthur, Ken, Hegarty, Shauna, Ali, Ahlam Abdunnabi, Furlong, Fiona, McCarthy, Helen, Ellis, Ian O., Green, Andrew R., Rakha, Emad, Young, Leonie, Kunkler, Ian, Thomas, Jeremy, Jack, Wilma et al (Select to open full list), 2015.

All authors for FKBPL : a marker of good prognosis in breast cancer

Nelson, Laura, McKenn, Hayley D., Marshall, A. (Andrea)?, Mulrane, Laoighse, Starczynski, Jane, Storr, Sarah J., Lanigan, Fiona, Byrne, Christopher, Arthur, Ken, Hegarty, Shauna, Ali, Ahlam Abdunnabi, Furlong, Fiona, McCarthy, Helen, Ellis, Ian O., Green, Andrew R., Rakha, Emad, Young, Leonie, Kunkler, Ian, Thomas, Jeremy, Jack, Wilma, Cameron, David, Jirström, Karin, Yakkundi, Anita, McClements, Lana, Martin, Stewart G., Gallagher, William M., Dunn, Janet A., Bartlett, John, O?Connor, Darran, Robson, Tracy

FKBPL : a marker of good prognosis in breast cancer. Oncotarget, 6 (14), pp. 12209-12223
Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M., Dunn, Janet A., 2014. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, 15 (1), pp. 78-86
Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon et al (Select to open full list), 2014.

All authors for Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon, Dunn, Janet A., Provenzano, Elena, Caldas, Carlos

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. The Lancet Oncology, Volulme 15 (2), pp. 201-212
Molyneux, Elizabeth, Merrick, Blair, Khanim, Farhat L., Banda, Kondwani, Dunn, Janet A., Iqbal, Gulnaz, Bunce, Christopher M., Drayson, Mark T., 2014. Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi ; an open-label, single-arm, phase 2 study (ISRCTN34303497). British Journal of Haematology, 164 (6), pp. 888-890
Abraham, J. E., Guo, Q., Dorling, L., Tyrer, J., Ingle, S., Hardy, R., Vallier, A.-L., Hiller, Louise, Burns, R., Jones, L., Bowden, S. J., Dunn, Janet A., Poole, C. J., Caldas, C., Pharoah, P. P. D., Earl, Helena M., 2014. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clinical Cancer Research, 20 (9), pp. 2466-2475
Corrie, Pippa G., Marshall, A. (Andrea)?, Dunn, Janet A., Middleton, Mark R., Nathan, Paul D., Gore, Martin, Davidson, Neville, Nicholson, Steve, Kelly, Charles G., Marples, Maria, Danson, Sarah J., Marshall, Ernest, Houston, Stephen J., Board, Ruth E., Waterston, Ashita M., Nobes, Jenny P., Harries, Mark, Kumar, Satish, Young, Gemma, Lorigan, Paul, 2014. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M) : preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. The Lancet Oncology, 15 (6), pp. 620-630
Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon et al (Select to open full list), 2014.

All authors for Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo) : an open-label, 2×2 factorial randomised phase 3 trial

Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon, Dunn, Janet A., Provenzano, Elena, Caldas, Carlos

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo) : an open-label, 2×2 factorial randomised phase 3 trial. The Lancet Oncology, 15 (2), pp. 201-212
Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2014. A qualitative systematic review exploring lay understanding of cancer by adults without a cancer diagnosis. Journal of Advanced Nursing, 70 (8), pp. 1688-1701
Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014.

All authors for Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P., Caldas, C.

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
Wason, J., Marshall, A. (Andrea)?, Dunn, Janet A., Stein, R. C., Stallard, Nigel, 2014. Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. British Journal of Cancer, 110 (8), pp. 1950-1957
Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014.

All authors for Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P., Caldas, C.

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
Dunn, Janet A., Donnelly, P. K., Marshall, A. (Andrea)?, Wilcox, M., Watson, E., Young, Annie M., Balmer, Claire E., Ramirez, M., Hartup, S., Maxwell, A.J., Evans, A. J., 2014. Follow-up in early breast cancer ? a surgical and radiological perceptive. Clinical Oncology, 26 (10), pp. 625-629
Taylor-Phillips, Sian, Wallis, Matthew G., Parsons, Helen, Dunn, Janet A., Stallard, Nigel, Campbell, Helen, Sellars, Sarah, Szczepura, Ala, Gates, Simon, Clarke, Aileen, 2014. Changing case order to optimise patterns of performance in mammography screening (CO-OPS) : study protocol for a randomized controlled trial. Trials, 15
Bryan, Richard T., Zeegers, Maurice P., van Roekel, Eline H., Bird, Deborah, Grant, Margaret R., Dunn, Janet A., Bathers, Sarah, Iqbal, Gulnaz, Khan, Humera S., Collins, Stuart I., Howman, Andrew, Deshmukh, Nayneeta S., James, Nicholas D., Cheng, Kar Keung, Wallace, D. Michael A., 2013. A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. BJU International, 112 (2), pp. 169-175
Bartlett, J., Canney, P., Campbell, A. M., Cameron, D., Donovan, Jenny, Dunn, Janet A., Earl, Helena M., Francis, A., Hall, P., Harmer, V., Higgins, Helen B., Hillier, L., Hulme, C., Hughes-Davies, Luke, Makris, A., Morgan, A., McCabe, Chris, Pinder, S., Poole, Christopher J., Rea, D. et al (Select to open full list), 2013.

All authors for Selecting breast cancer patients for chemotherapy : the opening of the UK OPTIMA trial

Bartlett, J., Canney, P., Campbell, A. M., Cameron, D., Donovan, Jenny, Dunn, Janet A., Earl, Helena M., Francis, A., Hall, P., Harmer, V., Higgins, Helen B., Hillier, L., Hulme, C., Hughes-Davies, Luke, Makris, A., Morgan, A., McCabe, Chris, Pinder, S., Poole, Christopher J., Rea, D., Stallard, Nigel, Stein, R.

Selecting breast cancer patients for chemotherapy : the opening of the UK OPTIMA trial. Clinical Oncology, 25 (2), pp. 109-116
Bradley, A., Marshall, A., Stonehewer, L., Reaper, L., Parker, K., Bevan-Smith, E., Jordan, C., Gillies, J., Agostini, P., Bishay, E., Kalkat, M., Steyn, R., Rajesh, P., Dunn, Janet A., Naidu, B., 2013. Pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery. European Journal of Cardio-thoracic Surgery, 44 (4), pp. e266-e271
Ali, Alaa M., Provenzano, E., Barlett, J. M., Abraham, J., Driver, Kristy, Twelves, Chris, Munro, Alison F., Poole, Christopher, Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul, 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic subtypes in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
Ali, Alaa M., Provenzano, Elena, Bartlett, John M. S., Abraham, Jean, Driver, Kristy, Munro, Alison F., Twelves, Chris, Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul D., 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
Provenzano, E., Vallier, A. -L., Champ, R., Walland, K., Bowden, S. (Sarah), Grier, Anna, Fenwick, Nicola, Abraham, J. (Janet), Iddawela, M., Caldas, C., Hiller, Louise, Dunn, Janet A., Earl, Helena M., 2013. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer, 108 (4), pp. 866-872
McCaul, James A., Cymerman, James A., Hislop, Stuart, McConkey, Christopher C., McMahon, Jeremy, Mehanna, Hisham M., Shaw, Richard, Sutton, David N., Dunn, Janet A., 2013. LIHNCS - Lugol's iodine in head and neck cancer surgery : a multicentre, randomised controlled trial assessing the effectiveness of Lugol's iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in situ at mucosal resection margins of oral and oropharyngeal squamous cell carcinoma : study protocol for a randomised controlled trial. Trials, 14 (1)
Spooner, David A., Stocken, D. D., Jordan, S., Bathers, S., Dunn, Janet A., Jevons, C., Dodson, L., Morrison, J. M., Oates, G. D., Grieve, R. J., 2012. A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer. Clinical Oncology, Vol.24 (No.10), pp. 697-706
Iqbal, Gulnaz, Johnson, Mark R. D., Szczepura, Ala, Wilson, Sue, Gumber, Anil, Dunn, Janet A., 2012. UK ethnicity data collection for healthcare statistics : the South Asian perspective. BMC Public Health, Vol.12 (No.1)
Bradley, A., Marshall, A. (Andrea), Abdelaziz, M., Hussain, K., Agostini, P., Bishay, E., Kalkat, M., Steyn, R., Rajesh, P., Dunn, Janet A., Naidu, Babu V., 2012. Thoracoscore fails to predict complications following elective lung resection. European Respiratory Journal, Vol.40 (No.6), pp. 1496-1501
Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2012. Using photovoice to study the experience of living with and beyond the diagnosis of a poor prognostic cancer. BMJ Supportive & Palliative Care, 2 (Suppl_1), pp. A28-A28
Iqbal, Gulnaz, Johnson, Mark R. D., Szczepura, Ala, Gumber, Anil, Wilson, Sue, Dunn, Janet A., 2012. Ethnicity data collection in the UK: The healthcare professional's perspective. Diversity and equality in health and care, 9 (4), pp. 281-290
Nankivell, Paul, Dunn, Janet A., Langman, Michael J., Mehanna, Hisham M., 2012. Feasibility of recruitment to an oral dysplasia trial in the United Kingdom. Head & Neck Oncology, 4 (1)
Taggart, Frances M., Donnelly, Peter K., Dunn, Janet A., 2012. Options for early breast cancer follow-up in primary and secondary care : a systematic review. BMC Cancer, Vol.12 (No.1)
Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A. et al (Select to open full list), 2012.

All authors for Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A., McAdam, K., Foster, Liz, Leonard, R. C. F., Twelves, Chris, Cameron, D., Bartlett, J. M. S., Pharoah, P., Provenzano, E., Caldas, C., Poole, Christopher J.

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, Vol.107 (No.8), pp. 1257-1267
Tudur Smith, Catrin, Stocken, Deborah D., Dunn, Janet A., Cox, Trevor F., Ghaneh, Paula, Cunningham, David, Neoptolemos, John P., 2012. The value of source data verification in a cancer clinical trial. PLoS ONE, Vol.7 (No.12)
Campbell, H. E., Epstein, D., Bloomfield, D., Griffin, S., Manca, A., Yarnold, J., Bliss, J., Johnson, L., Earl, Helena M., Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Hopwood, P., Barrett-Lee, P., Ellis, P., Cameron, D., Harris, A. L., Gray, A. M., Sculpher, Mark J., 2011. The cost-effectiveness of adjuvant chemotherapy for early breast cancer : a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, Vol.47 (No.17), pp. 2517-2530
Ishak, K. Jack, Caro, J. Jaime, Drayson, Mark T., Dimopoulos, Meletios, Weber, Donna, Augustson, Bradley, Child, J. Anthony, Knight, Robert, Iqbal, Gulnaz, Dunn, Janet A., Shearer, Arran, Morgan, Gareth, 2011. Adjusting for patient crossover in clinical trials using external data : a case study of lenalidomide for advanced multiple myeloma. Value in Health, Vol.14 (No.5), pp. 672-678
Hiller, Louise, Dunn, Janet A., Higgins, Helen B., Ogburn-Storey, Emma, Loi, Shrushma, Vallier, Anne-Laure, Earl, Helena M., 2011. Optimising patient recall of adverse events over prolonged time periods. Trials, Vol.12 (Suppl.1)
Midgley, Rachel S., McConkey, Christopher C., Johnstone, Elaine C., Dunn, Janet A., Smith, Justine L., Grumett, Simon A., Julier, Patrick, Iveson, Claire, Yanagisawa, Yoko, Warren, Bryan, Langman, Michael J., Kerr, David J., 2010. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. Journal of Clinical Oncology, Vol.28 (No.30), pp. 4575-4580
Davidson, N., Gelber, R., Piccart, M., Pruneri, G., Pritchard, K., Ravdin, P., Robertson, J., Swain, S., Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., Nomura, Y., Ohashi, Y., Sakai, K., Sugimachi, K., Toi, M., Tominaga, T. et al (Select to open full list), 2010.

All authors for Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

Davidson, N., Gelber, R., Piccart, M., Pruneri, G., Pritchard, K., Ravdin, P., Robertson, J., Swain, S., Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., Nomura, Y., Ohashi, Y., Sakai, K., Sugimachi, K., Toi, M., Tominaga, T., Uchino, J., Yoshida, M., Haybittle, J. L., Leonard, C. F., Calais, G., Geraud, P., Collett, V., Davies, C., Delmestri, A., Sayer, J., Harvey, V. J., Holdaway, T. M., Kay, R. G., Mason, B. H., Forbes, J. F., Wilcken, N., Bauernhofer, T., Dubsky, P., Fesl, C., Fohler, H., Filipcic, L., Filipits, M., Fridrik, M., Gnant, M., Greil, R., Hegenbarth, K., Jakesz, R., Kwasny, W., Lang, A., Luschin-Ebengreuth, G., Marth, C., Menzel, C., Mlineritsch, B., Samonigg, H., Seifert, M., Sevelda, P., Singer, C., Steger, G. G., Stöger, H., Thaler, J., Tschmelitsch, J., Zielinski, C., Canney, P., Yosef, H. M. A., Focan, C., Peek, U., Oates, G. D., Powell, J., Durand, M., Mauriac, L., Di Leo, A., Dolci, S., Piccart, M. J., Masood, M. B., Parker, D., Price, J. J., Lindsay, M. A., Mackey, J., Martin, M., Hupperets, P. S. G. J., Bates, T., Blamey, R. W., Chetty, U., Ellis, I. O., Mallon, E., Morgan, D. A. L., Patnick, J., Pinder, S., Jackson, S., Ragaz, J., Berry, D., Broadwater, G., Cirrincione, C., Muss, H., Norton, L., Weiss, R. B., Abu-Zahra, H. T., Portnoj, S. M., Baum, M., Cuzick, J., Dunn, Janet A.

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute - Monographs, 41, pp. 162-177
Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M., Poole, Christopher, 2010. Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3), pp. 266-274
Cunningham, David, Chau, I., Stocken, Deborah D., Valle, J. W., Smith, D., Steward, William, Harper, Peter G., Dunn, Janet A., Tudur-Smith, C., West, J., Falk, S., Crellin, A., Adab, F., Thompson, J., Leonard, P., Ostrowski, J., Eatock, M., Scheithauer, W., Herrmann, R., Neoptolemos, John, 2009. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology, Vol.27 (No.33), pp. 5513-5518
Iqbal, Gulnaz, Gumber, Anil, Johnson, Mark R. D., Szczepura, Ala, Wilson, Sue, Dunn, Janet A., 2009. Improving ethnicity data collection for health statistics in the UK. Diversity in Health and Care, Vol.6 (No.4), pp. 267-285
Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A., Poole, Christopher, 2008. NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8), pp. 1226-1231
Biswas, S., Wrigley, J., East, C., Hern, A., Marshall, A. (Andrea), Dunn, Janet A., Lorigan, P., Middleton, M. (Mark), Corrie, P., 2008. A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update. ecancermedicalscience, Vol.2
Wardley, A. M., Hiller, Louise, Howard, H. C., Dunn, Janet A., Bowman, A., Coleman, R. E., Fernando, I. N., Ritchie, D. M., Earl, Helena M., Poole, Christopher J., 2008. tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer : a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, Vol.99 (No.4), pp. 597-603
Kerr, David J., Dunn, Janet A., Langman, Michael J., Smith, Justine L., Midgley, Rachel S. J., Stanley, Andrew, Stokes, Joanne C., Julier, Patrick, Iveson, Claire, Duvvuri, Ravi, McConkey, Christopher C., 2007. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. New England Journal Of Medicine, Vol.357 (No.4), pp. 360-369
Kerr, David J., Dunn, Janet A., Langman, Michael J., Smith, Justine L., Midgley, Rachel S. J., Stanley, Andrew, Stokes, Joanne C., Julier, Patrick, Iveson, Claire, Duvvuri, Ravi, McConkey, Christopher C., 2007. Rofecoxib and cardiovascular adverse eventsin adjuvant treatment of colorectal cancer. New England Journal Of Medicine, Vol.357 (No.4), pp. 360-369
Wilson, Sue, Dr, Wakelam, Michael J.O., Hobbs, Richard F. D., Ryan, Angela V., Dunn, Janet A., Redman, Val. D., Patrick, Fiona, Colbourne, Lynne, Martin, Ashley, 2006. Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population. BMC Cancer, Vol.6 (No.25)
Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Brunt, A. Murray, O'Reilly, Susan M., Crawford, S. Michael, Rea, Daniel W., Simmonds, Peter, Mansi, Janine L., Stanley, Andrew, Harvey, Peter, McAdam, Karen, Foster, Liz, Leonard, Robert C. F., Twelves, Chris, 2006. Epirubicin and cyclophosphamide, methotrexate,and fluorouracil as adjuvant therapy for early breast cancer. New England Journal of Medicine, Vol.355 (No.18), pp. 1851-1862
Ryan, Angela V., Wilson, Sue, Dr, Wakelam, Michael J. O., Warmington, Sally A., Dunn, Janet A., Hodgkin, Richard F. D., Martin, Ashley, Ismail, Tariq, 2006. A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancer. BMC Cancer, Vol.6 (No.251)
Drayson, M., Begum, G., Basu, S., Makkuni, S., Dunn, Janet A., Barth, N., Child, J. A., 2006. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma : an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood, 108 (6), pp. 2013-2019
Augustson, B. M., Begum, G., Dunn, Janet A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., Drayson, M. T., 2005. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 23 (36), pp. 9219-9226
Lovell, R., Dunn, Janet A., Begum, G., Barth, N. J., Plant, T., Moss, P. A., Drayson, M. T., Pratt, G., 2005. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. British Journal of Haematology, 130 (4), pp. 542-548
Bassi, C., Stocken, D. D., Olah, A., Friess, H., Buckels, J., Hickey, H., Dervenis, C., Dunn, Janet A., Deakin, M., Carter, R., Ghaneh, P., Neoptolemos, J. P., Büchler, M. W., 2005. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Digestive Surgery, 22 (5), pp. 353-363
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, Janet A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., Falconi, M., Pederzoli, P., Pap, A., Spooner, D., Kerr, D. J., Büchler, M. W., 2004. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New England Journal Of Medicine, 350 (12), pp. 1200-1210
McCloskey, E. V., Dunn, Janet A., Kanis, J. A., MacLennan, I. C. M., Drayson, M. T., 2002. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. British Journal of Haematology, 113 (4), pp. 1035-1043
Wallace, D. M. A., Bryan, R. T., Dunn, Janet A., Begum, G., Bathers, S., 2002. Delay and survival in bladder cancer. BJU International, 89 (9), pp. 868-878
Young, Annie M., Marsden, J., Goodman, A., Burton, Andrea, Dunn, Janet A., 2001. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-a) in metastatic melanoma. Clinical Oncology, 13 (6), pp. 458-465
Neoptolemos, J. P., Dunn, Janet A., Stocken, D. D., Almond, J., Link, K., Beger, H., Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., Fernandez-Cruz, L., Lacaine, F., Pap, A., Spooner, D., Kerr, D. J., Friess, H., Büchler, M. W., 2001. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer : a randomised controlled trial. Lancet, 358 (9293), pp. 1576-1585
Cooke, P. W., Dunn, Janet A., Latief, T., Bathers, S., James, N. D., Wallace, D. M. A., 2000. Long-term risk of salvage cystectomy after radiotherapy for muscle- invasive bladder cancer. European Urology, 38 (3), pp. 279-286
Herod, J., Burton, A., Buxton, J., Tobias, J., Luesley, D., Jordan, S., Dunn, Janet A., Poole, C. J., 2000. A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. Annals of Oncology, 11 (9), pp. 1175-1181
Langman, M. J. S., Dunn, Janet A., Whiting, J. L., Burton, A., Hallissey, M. T., Fielding, J. W. L., Kerr, D. J., 1999. Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Journal of Cancer, 81 (8), pp. 1356-1362
McCloskey, E. V., Maclennan, I. C. M., Drayson, M. T., Chapman, C., Dunn, Janet A., Kanis, J. A., 1998. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Journal of Haematology, 100 (2), pp. 317-325
Whiting, J. L., Hallissey, M. T., Fielding, J. W. L., Dunn, Janet A., 1998. Screening for gastric cancer by Helicobacter pylori serology : a retrospective study. British Journal of Surgery, 85 (3), pp. 408-411
Drayson, M. T., Chapman, C. E., Dunn, Janet A., Olujohungbe, A. B., Maclennan, I. C. M., 1998. MRC trial of a2b-interferon maintenance therapy in first plateau phase of multiple myeloma. British Journal of Haematology, 101 (1), pp. 195-202
Phillips, L., Lindley, D. V., Longford, N. T., Newby, M. J., Smith, T. M. F., Barnard, G. A., Cox, D. R., Leonard, T., Abdullah, S., Garthwaite, P., Abrams, K. R., Dunn, Janet A., Black, P. K., Blyth, S., Brown, P. J., Dickey, J. M., Flournoy, N., Smith, J. Q., 1998. Discussion on the papers on 'Elicitation'. Journal Of The Royal Statistical Society Series D -The Statistician, 47 (1), pp. 55-68
Bailey, N. P., Stuart, N. S. A., Bessell, E. M., Child, J. A., Norfolk, D., Fletcher, J., Grieve, R. J., Simmons, A. V., Barnard, D. L., Jack, A., Farish, J., Dunn, Janet A., Woodroffe, C. M., Stack, C., Cullen, M. H., 1998. Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMET) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Annals of Oncology, 9 (6), pp. 633-638
Etherington, L. J., Luesley, D. M., Shafi, M. I., Dunn, Janet A., Jordan, J. A., 1998. Cytological prediction of cervical intraepithelial neoplasia grade 3 : does size of the lesion matter?. Journal of Lower Genital Tract Disease, 2 (1), pp. 17-18
Etherington, I. J., Luesley, D. M., Shafi, M. I., Dunn, Janet A., Hiller, Louise, Jordan, J. A., 1997. Observer variability among colposcopists from the West Midlands region. BJOG: An International Journal of Obstetrics and Gynaecology, 104 (12), pp. 1380-1384
Shafi, M. I., Luesley, D. M., Jordan, J. A., Dunn, Janet A., Rollason, T. P., Yates, M., 1997. Randomised trial of immediate versus deferred treatment strategies for the management of minor cervical cytological abnormalities. BJOG: An International Journal of Obstetrics and Gynaecology, 104 (5), pp. 590-594
Etherington, I. J., Dunn, Janet A., Shafi, M. I., Smith, T., Luesley, D. M., 1997. Video colpography : a new technique for secondary cervical screening. BJOG: An International Journal of Obstetrics and Gynaecology, 104 (2), pp. 150-153
Van Geene, P., Varma, R., Dunn, Janet A., Chan, K. K., Luesley, D. M., 1996. The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer, 6 (3), pp. 219-224
Priestman, T. J., Dunn, Janet A., Brada, M., Rampling, R., Baker, P. G., 1996. Final results of the Royal College of Radiologists' Trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clinical Oncology, 8 (5), pp. 308-315
Bramhall, S. R., Stamp, G. W. H., Dunn, Janet A., Lemoine, N. R., Neoptolemos, J. P., 1996. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. British Journal of Cancer, 73 (8), pp. 972-978
Clinton, O. P., Priestman, T. J., Latief, T. N., Earl, H., Murphy, A., Blackledge, G. R. P., Dunn, Janet A., Baker, P., 1995. A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer. Clinical Oncology, 7 (4), pp. 251-256
Yu, C. C. W., Levison, D. A., Dunn, Janet A., Ward, L. C., Demonakou, M., Allum, W. H., Hallisey, M. T., 1995. Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. British Journal of Cancer, 71 (5), pp. 1106-1110
Liu, B., Earl, H. M., Poole, C. J., Dunn, Janet A., Kerr, D. J., 1995. Etoposide protein binding in cancer patients. Cancer Chemotherapy and Pharmacology, 36 (6), pp. 506-512
Shafi, M. I., Dunn, Janet A., Chenoy, R., Buxton, E. J., Williams, C., Luesley, D. M., 1994. Digital imaging colposcopy, image analysis and quantification of the colposcopic image. BJOG: An International Journal of Obstetrics & Gynaecology, 101 (3), pp. 234-238
Lynch, T. H., Waymont, B., Dunn, Janet A., Hughes, M. A., Wallace, D. M. A., 1994. Rapid diagnostic service for patients with haematuria. British Journal of Urology, 73 (2), pp. 147-151
Luesley, D., Blomfield, P., Dunn, Janet A., Shafi, M., Chenoy, R., Buxton, J., 1994. Cigarette smoking and histological outcome in wom with mildly dyskaryotic cervical smears. BJOG: An International Journal of Obstetrics & Gynaecology, 101 (1), pp. 49-52
Stonelake, P. S., Bundred, N. J., Neoptolemos, N. P., Baker, P. R., Baker, P. G., Gillespie, W. M., Dunn, Janet A., Spooner, D., Morrison, J. M., Oates, G. D., Lee, M. J. R., Neoptolemos, J. P., Chan, S. Y., 1994. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. European Journal of Cancer Care, 30 (1), pp. 5-11
Lynch, T. H., Waymont, B., Dunn, Janet A., Hughes, M. A., Wallace, D. M. A., 1994. Repeat testing for haematuria and underlying urological pathology. British Journal of Urology, 74 (6), pp. 730-732
Hutchinson, R., Tyrrell, P. N. M., Kumar, D., Dunn, Janet A., Li, J. K. W., Allan, R. N., 1994. Pathogenesis of gall stones in Crohn's disease : an alternative explanation. Gut, 35 (1), pp. 94-97
Maclennan, I. C. M., Drayson, M., Dunn, Janet A., 1994. Current issues in cancer : multiple myeloma. BMJ Open, 308 (6935), pp. 1033-1036
Hallissey, M. T., Dunn, Janet A., Ward, L. C., Allum, W. H., 1994. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer : five-year follow-up. The Lancet, 343 (8909), pp. 1309-1312
Silverman, D. T., Dunn, Janet A., Hoover, R. N., Schiffiman, M., Lillemoe, K. D., Schoenberg, J. B., Brown, L. M., Greenberg, R. S., Hayes, R. B., Swanson, G. M., Wacholder, S., Schwartz, A. G., Liff, J. M., Pottern, L. M., 1994. Cigarette smoking and pancreas cancer : a case-control study based on direct interviews. Journal of the National Cancer Institute, 86 (20), pp. 1510-1516
Hallissey, M. T., Dunn, Janet A., Fielding, J. W. L., 1994. Evaluation of pepsinogen a and gastrin-17 as markers of gastric cancer and high-risk pathologic conditions. Scandinavian Journal of Gastroenterology, 29 (12), pp. 1129-1134
Hallissey, M. T., Jewkes, A. J., Dunn, Janet A., Ward, L., Fielding, J. W. L., 1993. Resection-line involvement in gastric cancer : a continuing problem. British Journal of Surgery, 80 (11), pp. 1418-1420
Stonelake, P. S., Powell, J., Dunn, Janet A., Warwick, Jane, Bramhall, S. R., Neoptolemos, J. P., Baker, P. R., Morrison, J. M., 1993. Influence of timing of surgery during menstrual, cycle on survival of premenopausal women with operable breast cancer. The Breast, 2 (3), pp. 201-202
Shafi, M. I., Dunn, Janet A., Finn, C. B., Kehoe, S., Buxton, E. J., Jordan, J. A., Luesley, D. M., 1993. Characterization of high- and low-grade cervical intraepithelial neoplasia. International Journal of Gynecological Cancer, 3 (4), pp. 203-207
Wallace, L. M., Priestman, S. G., Dunn, Janet A., Priestman, T. J., 1993. The quality of life of early breast cancer patients treated by two different radiotherapy regimens. Clinical Oncology, 5 (4), pp. 228-233
Waymont, B., Lynch, T. H., Dunn, Janet A., Bathers, S., Wallace, D. M. A., 1993. Treatment Preferences of urologists in Great Britain and Ireland in the management of prostate cancer. British Journal of Urology, 71 (5), pp. 577-582
Deakin, M., Gunson, B. K., Dunn, Janet A., McMaster, P., Tisone, G., Warwick, Jane, Buckels, J. A., 1993. Factors influencing blood transfusion during adult liver transplantation. Annals of The Royal College of Surgeons of England, 75 (5), pp. 339-344
Finn, C. B., Dunn, Janet A., Buxton, E. J., Luesley, D. M., Shafi, M., 1993. Can we predict a high risk group in ovarian cancer?. International Journal of Gynecological Cancer, 3 (4), pp. 226-230
Shafi, M. I., Dunn, Janet A., Buxton, E. J., Finn, C. B., Jordan, J. A., Luesley, D. M., 1993. Abnormal cervical cytology following large loop excision of the transformation zone : a case controlled study. Obstetrical and Gynecological Survey, 48 (8), pp. 546-548
Blomfield, P. I., Buxton, J., Dunn, Janet A., Luesley, D. M., 1993. Pregnancy outcome after large loop excision of the cervical transformation zone. American Journal of Obstetrics and Gynecology, 169 (3), pp. 620-625
de Takats, P. G., Dunn, Janet A., Kerr, D. J., Morrison, J. M., 1993. Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse. Cancer Treatment Reviews, 19 (Supplement B), pp. 11-19
Brown, R. D., Joshua, D. E., Nelson, M., Gibson, J., Dunn, Janet A., MacLennan, I. C. M., 1993. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma : results from the MRC (UK) V Trial. British Journal of Haematology, 84 (2), pp. 238-241
Waymont, B., Lynch, T. H., Dunn, Janet A., Emtage, L. A., Arkell, D. G., Wallace, D. M. A., Blackledge, G. R. P., 1992. Phase III randomised study of Zoladex versus Stilboestrol in the treatment of advanced prostate cancer. British Journal of Urology, 69 (6), pp. 614-620
MacLennan, I. C. M., Chapman, C., Dunn, Janet A., Kelly, K., 1992. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Lancet, 339 (8787), pp. 200-205
Ward, L. C., Fielding, J. W. L., Dunn, Janet A., 1992. The selection of cases for randomised trials : a registry survey of concurrent trial and non-trial patients. British Journal of Cancer, 66 (5), pp. 943-950
Lynch, T. H., Waymont, B., Dunn, Janet A., Wallace, D. M. A., 1992. Urologists' attitudes to the management of bladder cancer. British Journal of Urology, 70 (5), pp. 522-525
Oláh, K. S., Dunn, Janet A., Gee, H., 1992. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors : the result of a retrospective study of 423 cases of uterine sarcoma. BJOG: An International Journal of Obstetrics & Gynaecology, 99 (7), pp. 590-594
Finn, C. B., Luesley, D. M., Buxton, E. J., Blackledge, G. R., Kelly, K., Dunn, Janet A., Wilson, S., 1992. Is stage I epithelial ovarian cancer over-treated both surgically and systematically? Results of a five-year cancer registry review. Obstetrical and Gynecological Survey, 47 (7), pp. 491-493
Finn, Catherine B., Luesley, D. M., Buxton, E. J., Blackledge, G. R., Kelly, K., Dunn, Janet A., Wilson, S., 1992. Is Stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. BJOG: An International Journal of Obstetrics and Gynaecology, 99 (1), pp. 54-58
Shafi, M. I., Finn, C. B., Luesley, D. M., Jordan, J. A., Dunn, Janet A., 1991. Lesion size and histology of atypical cervical transformation zone. BJOG: An International Journal of Obstetrics & Gynaecology, 98 (5), pp. 490-492
Finn, C. B., Ward, K., Luesley, D. M., Dunn, Janet A., Redman, C. W. E., 1991. Qualitative and quantitative analysis of peritoneal fluids from women with gynecologic diseases. Comparison of cytology and flow cytometry for the detection of malignancy in lavage and ascitic fluids. Analytical and Quantitative Cytology and Histology, 13 (3), pp. 182-186
Oláh, K. S., Gee, H., Blunt, S., Dunn, Janet A., Kelly, K., Chan, K. K., 1991. Retrospective analysis of 318 cases of uterine sarcoma. European Journal of Cancer and Clinical Oncology, 27 (9), pp. 1095-1099
Lynch, T. H., Waymont, B., Beacock, C. J. M., Dunn, Janet A., Hughes, M. A., Wallace, D. M. A., 1991. Follow up after transurethral resection of prostate : who needs it?. British Medical Journal, 302 (6767)
Valori, R. M., Hallisey, M. T., Dunn, Janet A., 1990. Power of oesophageal peristalsis can be controlled voluntarily. Gut, 32 (3), pp. 236-239
Berisa, F., Beaman, M., Adu, D., McGonigle, R. J. S., Michael, J., Downing, R., Fielding, J. W. L., Dunn, Janet A., 1990. Prognostic factors in acute renal failure following aortic aneurysm surgery. QJM, 76 (1), pp. 689-698
Wallace, D. M. A., Raghavan, D., Kelly, K. A., Sandeman, T. F., Conn, I. G., Teriana, N., Dunn, Janet A., Boulas, J., Latief, T., 1990. Neo-adjuvant (pre-emptive) Cisplatin therapy in invasive transitional cell carcinoma of the bladder. British Journal of Urology, 67 (6), pp. 608-615

Friede, Tim, Dunn, Janet A., Stallard, Nigel, 2008. Clinical trials in oncology. In Missailidis, Sotiris (ed.), Anticancer therapeutics, Oxford ; Hoboken, NJ, Wiley-Blackwell, pp. 365-375

Young, Annie M., Phillips, J., Marshall, A., Grumett, J., Dunn, Janet A., Lowe, S., Chapman, O., Lokare, A., 2014. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. 7th ITHIC, Published in Thrombosis Research, pp. S220-S220
Meads, D. M., McCabe, C., Hulme, C. T., Edlin, R., Kharroubi, S. A., Browne, C., Ford, H., Dunn, Janet A., Marshall, A., 2014. Cost-utility of cancer therapies - the 'cost' of different utility generation strategies. ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 08 - 12 Nov 2014, Published in Value in Health: The Journal of The International Society for Pharmacoeconomic and Outcomes Research
Balmer, Claire E., Dunn, Janet A., Griffiths, Frances, 2012. Using photographs to describe what it's like to live with and beyond cancer. INVOLVE 2012 conference, East Midlands Conference Centre, Nottingham, 13-14 Nov 2012
Balmer, Claire E., Dunn, Janet A., Griffiths, Frances, 2010. How does contemporary health care meet the needs of those living with a poor prognostic cancer and does it need improving?. ESRC Research Methods Conference
Balmer, Claire E., Dunn, Janet A., Griffiths, Frances, 2010. Using photography to find out about the needs of often neglected populations. INVOLVE Conference 2010, 2010
Dunn, Janet A., Wilcox, M., Taggart, Frances M., Hulme, Claire, Tritter, Jonathan, Austoker, Joan, Mossman, Jean, Fide, Jane, Balmer, Claire E., Beaver, Kinter, Donnelly, Peter, 2009. Involving patients in clinical trial design : the experience of the UK Ibreast early breast cancer follow-up trial. Society for Clinical Trials Annual 30th Annual Meeting 2009, Atlanta, Georgia, USA, 2009
Bartlett, J. M. S., Munro, A., Dunn, Janet A., Hiller, Louise, Jordan, S., Twelves, Chris, Cameron, D. A., Thomas, J., Campbell, F., Rea, D. W., Provenzano, E., Pharoah, P., Caldas, Carlos, Earl, Helena M., Poole, Christopher J., 2009. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEA Tadjuvant breast cancer trial. 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008, Published in Cancer Research, pp. 74S-74S
Spooner, David A., Stocken, D. D., Jordan, S., Bathers, S., Dunn, Janet A., Jevons, C., Morrison, M., Oates, G., Grieve, R., 2009. A randomised controlled trial to evaluate both the role and optimal fractionation of radiotherapy in the conservative management of early breast cancer.. 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008, Published in Cancer Research, pp. 338S-338S
Bartlett, J. M. S., Munro, A., Desmedt, Christine, Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, Helena M., Poole, Christopher J., Shepherd, Lois, Cardoso, Fatima, Caldas, Carlos, Twelves, Chris, Pritchard, K., Rea, D. W., di Leo, A., 2009. Duplication of chromosome 17 CEP predicts for anthracycline benefit: a meta-analysis of 4 trials. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 09-13, 2009, Published in Cancer Research, pp. 716S-716S
Biswas, S., East, C., A'Hern, A., Marshall, A. (Andrea), Dunn, Janet A., Lorigan, Paul, Middleton, M. (Mark), Corrie, P., 2008. Adjuvant bevacizumab is safe treatment for melanoma patients at high risk of recurrence. 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, 12-16 Sept 2008, Published in Annals of Oncology, pp. 245-246
Dunn, Janet A., Balmer, Claire E., McConkey, Christopher C., Nutting, Chris, Fisher, Sheila, Wong, Wai Lup, MacLennan, Ken, McCabe, Chris, Hulme, Claire, Mehanna, Hisham M., 2008. PET-NECK : setting up a collaborative clinical trial in a rare disease site. Society for Clinical Trials Annual Meeting 2008
Ishak, K., Deniz, B., Drayson, Mark T., Morgan, G. J., Augustson, B., Child, A., Begum, Gulnaz, Dunn, Janet A., Shearer, Arran, Caro, J. Jaime, 2008. Modeling overall survival in the event of patient cross-over from dexamethasone to lenalidomide in phase III multiple myeloma trials. 48th Annual Scientific Meeting of the British-Society-for-Haematology, Glasgow, Scotland, Apr 07-09, 2008, Published in British Journal of Haematology, pp. 121-121
Midgley, Rachel S. J., McConkey, Christopher C., Langman, Michael J., Smith, Justine L., Julier, Patrick, Iveson, Claire, Johnstone, Elaine, Chen, Xiao-he, Dunn, Janet A., Kerr, David J., 2008. VICTOR : a phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection. 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, 12-16 Sept 2008, Published in Annals of Oncology, pp. 1-1
Drayson, M. T., Augustson, B. M., Begum, G., Dunn, Janet A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., 2007. Survival from relapse and the influence of therapy. 11th International Myeloma Workshop/4th International Workshop on Wladenestroms Macroglobulinemia, Kos Isl, Greece, June 25-30, 2007, Published in Haematologica, pp. 173-173
Hiller, Louise, Fenwick, N., Vallier, A. L., Dunn, Janet A., Hilborne, S., Jones, L., Abraham, J., Iddawela, M., Caldas, Carlos, Earl, Helena M., 2007. The challenges of using radiological 'tumour response' as an endpoint in Neo-tAnGo: a national neo-adjuvant chemotherapy breast cancer trial. 10th Nottingham International Breast Cancer Conference, Nottingham, England, September 18-20, 2007, Published in European Journal of Cancer Supplements, pp. 33-34
Poole, C. J., Hiller, Louise, Howard, H. C., Loi, Shrushma, Dunn, Janet A., Canney, P., Wardley, A. M., Crown, J. P., Coleman, R. E., Verrill, M. W., Ellis, P. A., Leonard, R. C., Spooner, David A., Earl, Helena M., 2006. Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 14-17, 2006, Published in BREAST CANCER RESEARCH AND TREATMENT, pp. S114-S114
Fielding, J. W. L., Dunn, Janet A., Baker, P. G., Davis, J. G., Billingham, L. J., Hallisey, M. T., Langham, M. J., 1997. An interim report of the cimetidine therapy in stomach cancer (CIS) study. GI Cancer

Jones, Lyn I., Taylor-Phillips, Sian, Geach, Rebecca, Harding, Sam A., Marshall, ?A., McKeown-Keegan, Sadie, Dunn, Janet A., 2022. Re: The potential of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening : a systematic review and meta-analysis. A reply. Clinical Radiology, W.B. Saunders Co. Ltd, pp. 73-75
Atkin, C., Drayson, M., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Higgins, Helen B., Dunn, Janet A., Bowcock, S., 2018. Presenting symptoms of patients with multiple myeloma : data from the TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial. British Journal of Haematology, Wiley, pp. 5-211
Stein, R. C., Makris, A., Hughes-Davies, L., Macpherson, I. R., Hall, P. S., Cameron, D. A., Earl, H. M., Pinder, S. E., Poole, C. J., Rea, D. W., McIntosh, S., Harmer, V., Morgan, A., Rooshenas, L., Conefrey, C., Donovan, J. L., Hulme, C, McCabe, Chris, Stallard, Nigel, Campbell, A. et al (Select to open full list), 2018.

All authors for OPTIMA : A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast cancer

Stein, R. C., Makris, A., Hughes-Davies, L., Macpherson, I. R., Hall, P. S., Cameron, D. A., Earl, H. M., Pinder, S. E., Poole, C. J., Rea, D. W., McIntosh, S., Harmer, V., Morgan, A., Rooshenas, L., Conefrey, C., Donovan, J. L., Hulme, C, McCabe, Chris, Stallard, Nigel, Campbell, A., Higgins, Helen B., Bartlett, J. M. S., Marshall, A. (Andrea)?, Dunn, Janet A.

OPTIMA : A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast cancer. Cancer Research, American Association of Cancer Research
Bowcock, S., Atkin, C., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M., Co-Investigators, Teamm, 2018. Does a long diagnostic pathway in myeloma lead to more advanced disease at presentation? An analysis from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, Wiley, pp. 5-211
Chicca, I. J., Heaney, J. L. J., Iqbal, Gulnaz, Bowcock, S., Planche, T., Wood, J., Raynes, K., Hawkey, P., Pratt, G., Yong, K., Dunn, Janet A., Drayson, M. T., 2018. Major changes in levels of regulatory cytokines and functional antibodies contribute to severe immunodeficiency of myeloma patients and persist at one year post diagnosis. Haematologica, Fondazione Ferrata Storti, pp. 1-48
Young, Annie M., Marshall, A. (Andrea)?, Thirlwall, Jenny, Chapman, O., Lokare, A., Hills, Claire E., Hale, D., Dunn, Janet A., Kakkar, A., Levine, M., Select-d Collaborative, Group, 2018. Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism : results of the 'select-d' Pilot Trial. Thrombosis Research, Pergamon-Elsevier Science Ltd
Bowcock, S., Planche, T., Iqbal, Gulnaz, Pratt, G., Yong, K., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M., Co-Investigators, Teamm, 2018. Levofloxacin prophylaxis in newly diagnosed myeloma reduces febrile episodes and death without increasing healthcare associated infections : results from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, Wiley, pp. 5-211
Dunn, Janet A., Marshall, A. (Andrea)?, Ramirez, M., Evans, A., Donnelly, P., 2017. Value of a sister observational cohort alongside a randomised controlled trial with an internal feasibility phase. Trials, Biomed Central Ltd
Mistry, Pankaj, Dunn, Janet A., Marshall, A. (Andrea)?, 2017. A literature review of the use of adaptive design methods in oncology trials. Trials, Biomed Central Ltd
Morgan, A., Ah-See, M. L., Hunter, M., Armes, J., Filshie, J., Turner, L., Morris, C., Flint, M., Dunn, Janet A., Pennery, E., Sassarini, J., Stanway, S., Noble, J., Andreia, F., Morgan, D., Khambhaita, P., Fenlon, D., 2017. Comparing clinician and patient perspectives in the management of hot flushes in UK breast cancer patients. BJOG-an International Journal of Obstetrics and Gynaecology, Wiley, pp. 100-102
Taylor-Phillips, Sian, Jenkinson, David J., Wallis, Matthew, Dunn, Janet A., Clarke, Aileen, 2017. Pragmatic integrated randomised controlled trials in screening : experience from a trial in 1.2million women attending breast screening. Trials, Biomed Central Ltd
Wong, W. L., Dunn, Janet A., Mehanna, H., 2016. The role of PET CT in the management of advanced nodal head neck cancer post chemoradiotherapy. Translational Cancer Research, AME Publishing Company, pp. S932-S932
Mehanna, H., Wong, W. L., Dunn, Janet A., 2016. Management of Advanced Head and Neck Cancer REPLY. New England Journal of Medicine, Massachusetts Medical Society, pp. 492-493
Smith, A. F., Hall, P. S., Hulme, Charles, McConkey, Christopher C., Dunn, Janet A., Rahman, J., Mehanna, H., 2016. PET-CT surveillance for advanced head and neck cancer : a cost-effective alternative to planned neck dissection?. Annals of Oncology, Oxford University Press
Rea, D., Francis, A., Poole, C., Brookes, C., Stein, R., Bartlett, J., Dunn, Janet A., Canney, P., Sutton, R., Daoud, R., Hallissey, M., Achuthan, R., Grant, M., Babrah, J., Smith, S., Fraser, J., Desai, A., Al Dubaisi, M., Patel, A., Bristol, J. et al (Select to open full list), 2016.

All authors for NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole plus /- celecoxib in the treatment of ER positive postmenopausal early breast cancer

Rea, D., Francis, A., Poole, C., Brookes, C., Stein, R., Bartlett, J., Dunn, Janet A., Canney, P., Sutton, R., Daoud, R., Hallissey, M., Achuthan, R., Grant, M., Babrah, J., Smith, S., Fraser, J., Desai, A., Al Dubaisi, M., Patel, A., Bristol, J., Chandrasekharan, S., Prest, C., Jewkes, A., Investigators, Neo-Excel

NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole plus /- celecoxib in the treatment of ER positive postmenopausal early breast cancer. Cancer Research, American Association of Cancer Research
Mehanna, H., Wong, W. L., Dunn, Janet A., 2016. Management of advanced nodal disease in patients treated with primary chemoradiotherapy. Current Opinion in Oncology, Lippincott Williams and Wilkins, pp. 201-204
Mehanna, H., Franklin, N., Compton, N., Robinson, M., Powell, N., Biswas-Baldwin, N., Paleri, V., Hartley, A., Fresco, L., Al-Booz, H., Junor, E., El-Hariry, I., Roberts, S., Harrington, K., Ang, K. K., Dunn, Janet A., Woodman, C., 2016. Geographic variation in human papillomavirus-related oropharyngeal cancer : data from 4 multinational randomized trials. Head and Neck, John Wiley and Sons Inc, pp. E1863-E1869
Stein, R. C., Makris, A., Hughes-Davies, L., Bartlett, J. M. S., Marshall, A. (Andrea)?, Hall, P. S., Campbell, A., Pinder, S. E., Cameron, D. A., Rea, D., Earl, H., MacPherson, I., Poole, C., Canney, P., Francis, A., Morgan, A., Stallard, Nigel, Hulme, C., McCabe, C., Dunn, Janet A., 2015. Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng Multi-parameter Analysis) prelim study. European Journal of Cancer Care, Wiley-Blackwell Publishing Ltd
Mehanna, H., Wong, W. L., McConkey, Christopher C., Rahman, J. K., Robinson, M., Hartley, A., Nutting, C., Powell, N., Al-Booz, H., Robinson, M., Junor, E., Hulme, C., Smith, A. F., Hall, P., Dunn, Janet A., 2015. Differences in the quality of life (QoL) and functional outcomes of treatment between HPV associated (HPV plus ) and HPV-patients receiving primary chemoradiotherapy in PET-NECK - a multi-centre randomized phase III controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNC) treated with primary radical chemoradiotherapy (CRT). European Journal of Cancer, Elsevier Science Ltd
Smith, A. F., Hall, P., Hulme, C., Dunn, Janet A., Rahman, J. K., McConkey, Christopher C., Mehanna, H., 2015. Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III randomized trial. Journal of Clinical Oncology, American Society of Clinical Oncology, pp. 6010-6010
Mehanna, H. M., Wong, W. L., McConkey, Christopher C., Rahman, J. K., Robinson, M., Hartley, A. G. J., Nutting, C., Powell, N., Al-Booz, H., Robinson, M., Junor, E., Hulme, C., Smith, A. F., Hall, P., Dunn, Janet A., 2015. PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT). Journal of Clinical Oncology, American Society of Clinical Oncology, pp. 6009-6009
Young, Annie M., Phillips, Jessica M., Hancocks, H., Marshall, A. (Andrea)?, Grumett, J., Dunn, Janet A., Chapman, Oliver, 2015. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology, American Society of Clinical Oncology
Hall, P., Smith, A., Hulme, C., Vargas-Palacios, A., Dunn, Janet A., Marshall, A. (Andrea)?, Bartlett, J., Stein, R., Cameron, D., McCabe, C., 2015. The use of early decision modelling and value of information analysis in an adaptive trial design : results from the OPTIMA preliminary study. Trials, Biomed Central Ltd
Mistry, Pankaj, Hiller, Louise, Iqbal, Gulnaz, Dunn, Janet A., 2015. Under-representation of male patients in breast cancer studies. Trials, Biomed Central Ltd
Bartlett, J. M. S., Stein, R. C., Bayani, J., Marshall, A. (Andrea)?, Dunn, Janet A., Campbell, A. F., Cunningham, C., Sobol, M., Hall, P., Rooshenas, L., Morgan, A., Poole, Christopher J., Pinder, S. E., Cameron, D. A., Stallard, Nigel, Donovan, J., McCabe, C., Hughes-Davies, L., Makris, A., 2015. Comparison of multiparameter tests in the UK OPTIMA-Prelim trial. Cancer Research, American Association of Cancer Research
Hiller, Louise, Marshall, A. (Andrea)?, Dunn, Janet A., 2015. Assessing violations of the proportional hazards assumption in Cox regression : does the chosen method matter?. Trials, Biomed Central Ltd
Dunn, Janet A., Marshall, A. (Andrea)?, Campbell, Amy, Cameron, D., Earl, H., Macpherson, I., Poole, C., Rea, D., Francis, A., Harmer, V., Morgan, A., Stallard, Nigel, Makris, A., Hughes-Davies, L., Stein, R., 2015. Practicalities of using an adaptive design for decision making within the optima trial : optimal personalized treatment of early breast cancer using multi-parameter tests. Trials, Biomed Central Ltd
Dunn, Janet A., Harris, B., Iqbal, Gulnaz, Wood, J., Mistry, Pankaj, O'Beirne-Elliman, J., Bowcock, S., Drayson, M., 2015. Use of patient diaries in conjunction with standard reporting methods : duplication of data or a valuable resource?. Trials, Biomed Central
Ah-See, M., Coles, C., Fenlon, D., Pennery, E., Dunn, Janet A., Morgan, A., 2014. The current management of vasomotor symptoms in breast cancer patients in the UK : clinician versus patient perspective. NCRI Breast CSG Working Party on Symptom Management (Vasomotor). European Journal of Cancer, Elsevier, pp. S88-S89
Young, Annie M., Dunn, Janet A., Chapman, O., Grumett, J., Marshall, A., Phillips, J., Lokare, A., 2014. SELECT-D : anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology, American Society of Clinical Oncology
Hiller, Louise, Vallier, A. L., Ogburn, E., Wardley, A. M., Cameron, D. A., Miles, D., Dunn, Janet A., Earl, H. M., 2014. Cardiology monitoring substudy in the PERSEPHONE trial : 6 versus 12 months of trastuzumab. Journal of Clinical Oncology, American Society of Clinical Oncology
Earl, H. M., Cameron, D. A., Miles, D., Wardley, A. M., Ogburn, E., Vallier, A. L., Loi, S., Higgins, H. B., Hiller, Louise, Dunn, Janet A., 2013. PERSEPHONE : duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer-six versus twelve months. Journal of Clinical Oncology, American Society of Clinical Oncology
Earl, H. M., Chin, S. F., Dunning, M., Iddawela, M., Rueda, O., Russell, R., Jones, L., Vallier, A. L., Hughes-Davies, L., Abraham, J., Chan, S., Skene, A., Benstead, K., Gallagher, C. J., Murray, N., Ritchie, D., Dunn, Janet A., Hiller, Louise, Provenzano, E., Caldas, C., 2013. Neo-tAnGo science : a translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy. Journal of Clinical Oncology, American Society of Clinical Oncology
Corrie, P., Marshall, A. (Andrea)?, Goonewardena, M., Dunn, Janet A., Middleton, M. R., Nathan, P. D., Gore, M. E., Davidson, N., Nicholson, S., Kelly, C. G., Marples, M., Danson, S., Marshall, E., Houston, S., Board, R. E., Waterston, A. M., Nobes, J., Harries, M., Barber, J., Lorigan, P., 2013. Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence : preplanned interim results for the AVAST-M trial. Journal of Clinical Oncology, American Society of Clinical Oncology
Ford, H., Marshall, A. (Andrea)?, Wadsley, J., Coxon, F. Y., Mansoor, W., Bridgwater, J. A., Madhusudan, S., Falk, S., Middleton, G. W., Swinson, D., Chau, I., Thompson, J., Blazeby, J. M., Cunningham, D., Kareclas, P., Dunn, Janet A., 2013. COUGAR-02 : a randomized phase 111 study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. Journal of Clinical Oncology, American Society of Clinical Oncology
Morgan, A., Fenlon, D., Coles, C., Armstrong, A., Randle, K., Thompson, A., Dunn, Janet A., 2013. Is it me or is it hot in here? Hot flushes (or flashes) : an unmet need. UK NCRI breast clinical studies group working party on symptom management (vasomotor). Cancer Research, American Association of Cancer Research
McCaul, J. A., Pendrill, A., Quantrill, J., Mehanna, H., McConkey, Christopher C., Dunn, Janet A., 2013. LIHNCS trial (Lugol's iodine in head and neck cancer surgery) : Interim recruitment and data report. Oral Oncology, Elsevier BV, pp. S37-S37
McCaul, J. A., Cymerman, J., Sutton, D. N., Shaw, R. J., Hislop, S., Adamson, J., Dunn, Janet A., 2013. Feasibility and surgeon acceptability of visualisation with Lugol's iodine (VILI) in the lihncs trial. Oral Oncology, Elsevier BV, pp. S35-S35
Corrw, P., Marshall, A. (Andrea)?, Goonewardena, M., Dunn, Janet A., Middleton, M. R., Nathan, P. D., Gore, M. E., Davidson, N., Nicholson, S., Kelly, C. E. G., Marples, M., Damson, S., Marshall, E., Houston, S., Board, R. E., Waterston, A. M., Nobes, J., Harries, M., Barber, J., Lorigan, P., 2013. AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence. Journal of Clinical Oncology, American Society of Clinical Oncology
Earl, H. M., Vallier, A. L., Ogburn-Storey, E., Cameron, D. A., Wardley, A. M., Miles, D., Loi, S., Hiller, Louise, Higgins, H. B., Dunn, Janet A., 2013. PERSEPHONE : duration of trastuzumab with chemotherapy in women with HER-2+ve early breast cancer. Cancer Research, American Association of Cancer Research
Earl, H. M., Blenkinsop, C., Grybowicz, L., Vallier, A. L., Cameron, D. A., Bartlett, J. M. S., Murray, N., Caldas, C., Thomas, J., Dunn, Janet A., Higgins, H. B., Hiller, L., Hayward, L., 2012. ARTemis trial - randomised trial with neo-adjuvant chemotherapy for patients with early breast cancer. Journal of Clinical Oncology, American Society of Clinical Oncology
Abdelaziz, M., Marshall, A. (Andrea)?, Hussain, K., Bradley, A., Agostini, P., Bishay, E., Kalkat, M., Steyn, R., Rajesh, P., Dunn, Janet A., Naidu, B., 2012. Can the thoracoscore and revised cardiac risk index predict outcomes?. Lung Cancer, Elsevier
Parsons, A., Bradley, A., Reaper, L., Jordan, C., Paul, A., Dowswell, G., Dunn, Janet A., Naidu, B., 2012. Patient's experiences of a pre and post surgery rehabilitation programme for lung cancer (Rehabilitation Of lung Cancer (ROC) programme) : a qualitative interview study. Lung Cancer, Elsevier Ireland LTD, pp. S64-S64
Earl, H. M., Cameron, D. A., Miles, D., Wardley, A. M., Ogburn, E. R. M., Vallier, A. L., Loi, S., Higgins, H. B., Hiller, L., Dunn, Janet A., 2012. PERSEPHONE : duration of trastuzumab with chemotherapy in women with HER2 positive early breast cancer. Cancer Research, American Association for Cancer Research
Dunn, Janet A., Kulkarni, R., Gouldesbrough, D., Mehanna, H., McMahon, J. M., Shaw, R., McCaul, J. A., 2012. LIHNCS trial : Lugol's iodine in head and neck cancer surgery. Journal of Clinical Oncology, American Society of Clinical Oncology
Poole, Christopher J., Marshall, A. (Andrea)?, Higgins, Helen B., Fletcher, J., Williams, S. J., Lo, N., Fernando, I. N., Osborne, R., Crawford, S. M., Rafii, S., Gill, S., Dunn, Janet A., 2012. Neo-escape : Neoadjuvant extended sequential chemotherapy with adjuvant postoperative treatment for epithelial nonmucinous advanced inoperable peritoneal malignancy. Journal of Clinical Oncology, American Society of Clinical Oncology
Earl, H. M., Cameron, D. A., Miles, D., Wardley, A. M., Ogburn, E., Vallier, A. L., Loi, S., Higgins, H. B., Hiller, L., Dunn, Janet A., 2012. The PERSEPHONE trial : duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer. Journal of Clinical Oncology, American Society of Clinical Oncology
Stein, R., Makris, A., Hughes-Davies, L., Dunn, Janet A., Bartlett, J. M. S., Donovan, J., McCabe, C., Cameron, D. A., Canney, P., Earl, H. M., Francis, A., Morgan, A., Pinder, S., Rea, D., Poole, C. J., Hall, P., Hiller, L., Stallard, Nigel, Higgins, H. B., 2012. OPTIMA prelim : optimal personalized treatment of early breast cancer using multiparameter analysis : preliminary study. Journal of Clinical Oncology, American Society of Clinical Oncology
Marshall, A. (Andrea), Dunn, Janet A., Fletcher, Julie, Higgins, Helen B., Poole, Christopher, 2011. The importance of planning for a seamless transition in an adaptive phase II randomised trial. Trials, Bio Med Central
Ali, A. M. G., Provenzano, E., Abraham, J., Bartlett, J. M., Poole, C. J., Hiller, L., Dunn, Janet A., Twelves, C., Earl, H. M., Caldas, C., Pharoah, P., 2011. Prognosis by breast cancer subtypes in patients treated with adjuvant chemotherapy in a clinical trial. Journal of Clinical Oncology, American Society of Clinical Oncology
Earl, H. M., Loi, S., Vallier, A. L., Hiller, L., Ogburn-Storey, E., Higgins, H., Dunn, Janet A., 2011. The PERSEPHONE trial : duration of trastuzumab with chemotherapy in women with HER2 positive early breast cancer. Changing the randomisation point to address potential barriers to recruitment. Cancer Research, American Association for Cancer Research
Morgan, G. J., Knight, R. D., Ishak, K. J., Drayson, M. T., Dimopoulos, M. A., Weber, D. M., Augustson, B., Child, J. A., Begum, G., Dunn, Janet A., Shearer, A., Caro, J. J., 2009. Addressing biased survival due to crossover in trials. Clinical Lymphoma & Myeloma, Elsevier, pp. S50-S51
Wong, Wai Lup, Nutting, Chris, Dunn, Janet A., Fisher, Sheila, MacLennan, Ken, MacCabe, Chris, Mehanna, Hisham M., 2009. Advanced head and neck cancer: is there a role for fluorodeoxyglucose PET/computed tomography?. Nuclear Medicine Communication, Lippincott Williams & Wilkins, pp. 2-4
Biswas, S., East, C., A'Hern, A., Marshall, A., Dunn, Janet A., Lorigan, P., Middleton, M., Corrie, P., 2008. Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial. Annals of Oncology, Oxford University Press, pp. 245-245
Ishak, K. J., Deniz, B., Drayson, M., Morgan, G. J., Augustson, B. M., Child, J. A., Begum, G., Dunn, Janet A., Shearer, A., Caro, J. J., 2008. A novel approach to adjust for the impact on survival resulting from patient cross-over from control to experimental treatment in clinical trials. Value in Health, Wiley-Blackwell Publishing, Inc, pp. A155-A155
Donnelly, Peter K., Hiller, Louise, Dunn, Janet A., 2008. Follow-up after breast cancer : national randomised controlled trial is needed. British Medical Journal, B M J Publishing Group, pp. 461-462
Donnelly, Peter K., Hiller, Louise, Dunn, Janet A., 2008. Need for the iBreast trial ? risk adjusted breast cancer follow-up trial. BMJ, BMJ Publishing Group Ltd
Kerr, David J., Dunn, Janet A., Langman, Michael J., Smith, J. L., Midgley, Rachel S. J., Iveson, Claire, McConkey, Christopher C., 2008. VICTOR : a phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection. Journal of Clinical Oncology, American Society of Clinical Oncology
Neoptolemos, J. P., Raraty, M. G. T., Ghaneh, P., Hickey, H., Stocken, D. D., Dunn, Janet A., Friess, H., Buchler, M. W., Schemmer, P., 2003. Adjuvant and additive therapy for cancer of the pancreas. Der Chirurg, Springer-Verlag, pp. 191-201
Neoptolemos, J. P., Cunningham, D., Friess, H., Bassi, C., Stocken, D. D., Tait, D. M., Dunn, Janet A., Dervenis, C., Lacaine, F., Hickey, H., Raraty, M. G. T., Ghaneh, P., Büchler, M. W., 2003. Adjuvant therapy in pancreatic cancer : historical and current perspectives. Annals of Oncology, Oxford University Press, pp. 675-692
Neoptolemos, J. P., Stocken, D., Dunn, Janet A., 2002. Letter to the editor 2 (multiple letters). Annals of Surgery, Lippincott Williams & Wilkins, pp. 696-697
Neoptolemos, J. P., Stocken, D. D., Dunn, Janet A., Almond, J., Beger, H. G., Pederzoli, P., Bassi, C., Dervenis, C., Fernandez-Cruz, L., Lacaine, F., Buckels, J., Deakin, M., Adab, F. A., Sutton, R., Imrie, C., Ihse, I., Tihanyi, T., Olah, A., Pedrazzoli, S., Spooner, D. et al (Select to open full list), 2001.

All authors for Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial

Neoptolemos, J. P., Stocken, D. D., Dunn, Janet A., Almond, J., Beger, H. G., Pederzoli, P., Bassi, C., Dervenis, C., Fernandez-Cruz, L., Lacaine, F., Buckels, J., Deakin, M., Adab, F. A., Sutton, R., Imrie, C., Ihse, I., Tihanyi, T., Olah, A., Pedrazzoli, S., Spooner, D., Kerr, D. J., Friess, H., Büchler, M. W.

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Annals of Surgery, Lippincott Williams & Wilkins, pp. 758-768
Drayson, M. T., Chapman, C. E., Olujohungbe, A., Dunn, Janet A., Maclennan, I. C. M., 1998. The MRC randomised trial of the use of a2b-interferon in first plateau phase in multiple myeloma. Cancer Research Therapy and Control
Dunn, Janet A., 1994. Seventeenth sir peter freyer memorial lecture and surgical symposium -September 18th & 19th, 1992. Irish Journal of Medical Science, pp. 68-92
Clarke, M., Gray, R., Dunn, Janet A., Maclennan, I., 1992. Combination chemotherapy for myelomatosis. The Lancet
Dunn, Janet A., 1992. Prognostic indices : who needs them?. Controlled Clinical Trials, Elsevier, pp. 381-382
Dunn, Janet A., Hallissey, M. T., 1992. Developing a prognostic index for stomach cancer. Controlled Clinical Trials, Elsevier
Dunn, Janet A., MacLennan, I., 1992. Comparing trials for the treatment of myelomatosis. Controlled Clinical Trials, Elsevier

Title	Funder	Award start	Award end
NIHR HTA via Derby NHS Tust: ATNEC?Axillary management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation after NEoadjuvant Chemotherapy	National Institute for Health Research (DoH)	01 Mar 2020	28 Feb 2030
ATNEC Y6-10	National Institute for Health Research (DoH)	01 Mar 2020	28 Feb 2030
NIHR HTA Stage 2 via UHCW: Evaluation of PeRsOnalised PrEhabilitation in acute myeloid Leukaemia (PROPEL).	National Institute for Health Research (NIHR DoH)	01 Sept 2022	31 Aug 2027
NIHR EME NIHR150502 via Bristol: : Diagnostic yield study to determine whether an abbreviated form of breast Magnetic Resonance Imaging (FAST MRI) can detect breast cancers missed by screening mammography for women at population risk of breast cancer with average mammographic density following their initial screening mammogram	National Institute for Health Research (NIHR DoH)	01 May 2023	31 Oct 2026
Mammo-50: Access to NHS Breast Screening Programme Data (NHS BSP) linked to IDEATE 72784 & 33985	NHS England	31 Oct 2023	30 Oct 2026
NIHR PGfAR via Newcastle: Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET)	National Institute for Health Research (DoH)	18 May 2020	17 May 2026
COBIx: Multi-site validation of automated AI tool for screening of large bowel endoscopic biopsy slides	National Institute for Health Research (NIHR DoH)	01 Apr 2023	31 Mar 2026
NIHR Programme Grant:Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET) Year 6 costs	National Institute for Health Research (DoH)	03 Feb 2020	02 Feb 2026
OPTIMA funded to UCL by VERACYTE	VERACYTE	01 Sept 2022	31 Dec 2025
Bloodwise: Repurposed drugs to improve haematological responses in Myelodysplastic Syndromes (MDS)	Bloodwise	01 Sept 2020	30 Jun 2025
NIHR HTA Stage 2: Volatile vs Total intravenous Anaesthesia for major non-cardiac surgery ? a randomised controlled triaL (VITAL)	National Institute for Health Research (NIHR DoH)	01 Nov 2020	30 Apr 2025
Veracyte Gift award for OPTIMA Investigator Meeting	VERACYTE	01 Feb 2024	31 Jan 2025
Make 2NDS COUNT: A national study of the experiences, information needs and attitudes to clinical research of patients living with secondary breast cancer in the UK (MSBC)	MAKE 2NDS COUNT	01 Jan 2021	30 Sept 2024
Breast Cancer Now: Mammographic Density Study	Breast Cancer Now	01 Mar 2019	31 Aug 2024
Mammographic surveilance in breast cancer patients aged 50 years or older (Mammo-50) (RMRCT 1081) Extension.Linked to IDEATE 33985	National Institute for Health Research (NIHR DoH)	01 Jul 2022	31 Dec 2023
NIHR HTA Costed Extenison: Digital Pathology_Linked to Main award on IDEATE 58038	National Institute for Health Research (NIHR DoH)	01 Nov 2021	30 Apr 2023
NIHR Senior Investigator Award 2018	National Institute for Health Research (DoH)	01 Apr 2019	31 Mar 2023
OPTIMA - 8 year extension	National Institute for Health Research (DoH)	01 Apr 2015	31 Mar 2023
Breast Cancer Now:SENTINUS: Multicentre phase II trial to assess technical feasibility and diagnostic performance of intradermal microbubbles and contrast-enhanced ultrasound (CEUS) plus core biopsy as a test to identify sentinel lymph node (SLN) metastases in patients with primary invasive breast cancer and a normal axillary grey-scale ultrasound. Lead by Maidstone NHS Trust	Breast Cancer Now	05 Oct 2020	04 Jan 2023
Mammographic surveillance in breast cancer patients aged 50 years or older	National Institute for Health Research (DoH)	01 Mar 2013	28 Feb 2022
NIHR HTA: Whole slide imaging in pathology	National Institute for Health Research (DoH)	01 Nov 2018	31 Oct 2021
PET NECK Data Re-Analysis	University of Birmingham	01 Feb 2017	31 Dec 2020
PERSEPHONE Trial: Amendment to Collaboration agreement. Linked to IDEATE record 50306.	National Institute for Health Research (NIHR DoH)	01 Apr 2007	31 Dec 2020
OPTIMAL study with Churchill Oxford NHS Trust	Oxford University Hospitals NHS Trust	01 Apr 2014	31 Mar 2020
De-escalate - Extension and supplement	Cancer Research UK	01 Sept 2017	31 Dec 2019
CRUK funded via Cambridge: AVAST-M - Extension	Cancer Research UK	01 Aug 2010	31 Dec 2019
Persephone extension and supplement	National Institute for Health Research (DoH)	01 Jul 2016	30 Jun 2019
Sponsorship of 2019 OPTIMA Investigator Meeting	Nanostring Technologies	04 Apr 2019	03 May 2019
Investigating interactions between the triad of Myeloma disease activity TEAMM EME	National Institute for Health Research (DoH)	01 Feb 2017	31 Jan 2019
ARTemis: Avastin randomised trial with nEo-adjuvant cheMotherapy for patinets with early breat cancer : Analysis Extension	Cambridge University Hospitals NHS Foundation Trust	01 Jul 2011	31 Dec 2018
Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER 2 negative breast cancer Artemis Year 9 Funding - staff - Late Phase Study	Cancer Research UK	01 May 2017	30 Apr 2018
ARTEMIS Pre-operative Avastin with neo-adjuvant chemotherapy Years 7,8 & 9 Support Funding	Cancer Research UK	01 May 2015	30 Apr 2018
Late Phase Study De-ESCALaTE-HPV Determination of Epidermal growth factor receptor-inhibitor(cetuximab) vs Standard Chemotherapy early and late toxicity Events - Year 6	Cancer Research UK	01 Sept 2016	31 Aug 2017
De-ESCALaTE-HPV - TrialDetermination of epidermal growth factor receptor-inhibitor (cetuximab) vs standard chemotherapy early and late toxicity events in human papilloma virus positive oropharyngeal carcinoma	Cancer Research UK	01 Mar 2011	28 Feb 2017
Research Capacity Funding Technology Assessment programme for Research linked to Mammo50 trial support	University Hospitals Coventry and Warwickshire NHS Trust	01 Jan 2014	31 Dec 2016
Second Recosting for extension of the Persephone HTA Trial	National Institute for Health Research (DoH)	01 Jul 2013	30 Jun 2016
OPTIMA Launch Meeting	Nanostring Technologies	01 Oct 2015	31 Dec 2015
Lugols Iodine in Head and Neck Cancer Surgery: A multi-centre randomised controlled trial assessing the effectiveness of Lugols Iodine - 15mth extension to the LIHNCS study.	Cancer Research UK	01 Oct 2014	31 Dec 2015
OPTIMA extra funds	National Institute for Health Research (DoH)	01 May 2015	31 Oct 2015
BAYER - Investigator led research proposal: SELECT-D Duration of anticoagulation therapy in SELECTeD patients with advanced cancer at risk of recurrence of venous thromboembolism -	Bayer plc	01 Oct 2012	30 Sept 2015
Support for WMS Clinical Trials Unit Facility	Wolfson Foundation	01 Jul 2007	30 Jun 2015
ARTEMIS Pre-operative Avastin with neo-adjuvant chemotherapy Year 6 extension	Cancer Research UK	01 May 2014	30 Apr 2015
PET-NECK Extension.	National Institute for Health Research (DoH)	01 Apr 2013	31 Mar 2015
TEAMM (HTA via Bham) Tackling Early Morbidity in Myeloma: Assessing the benefit of Antibiotic Prophylaxis and its effect on Healthcare Associated Infections	National Institute for Health Research (DoH)	01 Jan 2010	31 Dec 2014
Educational Grant towards randomisation costs for CAB B trial (led by University Hospital Birmingham)	Sanofi-Aventis	13 Dec 2012	12 Dec 2014
Improving breast cancer detection rates through understanding and modelling the patterns of radiologist performance	Breast Cancer Campaign	01 Oct 2011	30 Sept 2014
Supplement for year two of De-ESCALaTE-HPV trial. Award RMRCT0058, original proposal 28097	Cancer Research UK	01 Sept 2013	31 Aug 2014
CRUK/11/043: De-ESCALaTE-HPV - year 3	Cancer Research UK	01 Sept 2013	31 Aug 2014
Neo Escape funding for data manager	University Hospitals Coventry and Warwickshire NHS Trust	01 Apr 2013	31 Mar 2014
CRUK:via Bradford LUGOLS	Cancer Research UK	01 Apr 2010	31 Mar 2014
Variation: ATRemis:Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER2 negative breast cancer	Cancer Research UK	01 Jan 2010	31 Dec 2013
ARTemis: Avastin Randomised Trial with neo-adjuvent cheMotherapy for patients with early HER 2 negatIve breaSt cancer	Cancer Research UK	01 Dec 2008	30 Nov 2013
HTA FULL proposal: OPTIMA (Pilot Study)	National Institute for Health Research (DoH)	01 Sept 2012	31 Aug 2013
3 month extention of the Persephone HTA Trial	National Institute for Health Research (DoH)	01 Apr 2013	30 Jun 2013
Supplement from Cambridge University - PERSEPHONE Trial	NHS Health Technology Assessment (HTA)	20 Apr 2011	31 Mar 2013
Persephone - Adjuvant: Duration of Adjuvant Trastuzumab Study with Chemotherapy in Early Breast Cancer: Six Versus Twelve Months	NHS Health Technology Assessment (HTA)	01 Apr 2007	31 Mar 2013
Positron emission tomography - CT scan (pet-CT) guided watch and wait policy versus planned neck dissection for locally advanced (N2/N3) nodal metastases in patient with head neck squamous carcinoma treated with radical chemoradiotherapy.	NHS Health Technology Assessment (HTA)	01 Apr 2007	31 Mar 2013
Educational Conference Sponsorship agreement for Optima launch event	GE Healthcare	22 Jan 2013	28 Feb 2013
MRC DPFS via Queens University Belfast: Identifying markers of response to anti-oestrogen therapy	MRC	01 Feb 2011	31 Jan 2013
COUGAR 2 Extension - Andrea Marshall	Cancer Research UK	01 Nov 2010	31 Oct 2012
West Mids SHA Research Training Fellowship:How does contemporary health care meet the needs of those living with a poor prognostic cancer and does it need improving?	West Midlands Strategic Health Authority	01 Oct 2009	30 Sept 2012
Characterisation of cardiac changes before and after kidney transplantation using cardiopulmonary exercise testing echocardiograhpy	University Hospitals Coventry and Warwickshire NHS Trust	01 Aug 2009	30 Sept 2012
Statistical Analysis Agreement for ARTEMIS	Cancer Research UK	01 Jan 2009	30 Jun 2011
AVAST-M: Randomised Trial Evaluating the VEGF Inhibitor, Bevacinumab (Avastin), as Adjuvant Therapy Following Resection of AJCC Stage 11B (T4aNOMO), IIC (TB4NOMO) and III (TxN1-2MO) Melanoma	University of Cambridge	01 Aug 2006	31 Jul 2010
COUGAR-2: A Phase III Randomised Controlled Trial of Docetaxel Versus Active Symptom Control as Second Line Treatment in Advanced Gastric Cancer	Cancer Research UK	01 Jun 2007	31 May 2010
Neat Science - TOPO	University of Edinburgh	07 Jul 2008	06 Jul 2009
Neo-Tango Statistical Analysis	University of Cambridge	01 Apr 2008	31 Mar 2009
Proof concept study for use of topical oral cyclo-oxygenase inhibitors (cox-1) mouthwash.	Cancer Research UK	01 Apr 2007	31 Mar 2009
Neo-tango statistical analysis	Cancer Research UK	01 Mar 2007	28 Feb 2009
MK 966,201 ViP data analysis.	Merck & Co Inc	19 Jun 2006	31 Dec 2007
Travel Award for Improving Data Collection for Statistics of Cancer Incidence, Management, Mortality and Survival in the UK	Cancer Research UK	01 Feb 2007	30 Nov 2007
Improving Ethnic Data Collection for Statistics of Cancer Incidence, Management, Mortality and Survival in the UK.	Cancer Research UK	01 Sept 2006	30 Jun 2007
CRUK Travel Award for R Millwood - Society of Clinical Trials Meeting May 2006	Cancer Research UK	01 Sept 2006	31 May 2007
Reimbursement of secondment funds for Miss Andrea Burton to work on project at Oxford	Cancer Research UK	01 Oct 2005	30 Sept 2006